Therapeutic combinations comprising ubiquitin-specific processing protease 1 (USP1) inhibitors and chemotherapeutic agents

By combining USP1 inhibitors and chemotherapeutic agents, the shortcomings of existing cancer treatment methods in delaying and preventing tumor rebound are solved, and more effective tumor control and reducing therapeutic toxicity are achieved.

CN119013018APending Publication Date: 2024-11-22KSQ THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032855.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-10-24
Filing Date
2023-04-07
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing cancer treatments remain inadequate for more effective treatment of cancer, especially in delaying, reducing and preventing tumor rebound.

Method used

A composition has been developed, including ubiquitin-specific processing protease 1 (USP1) inhibitors and chemotherapeutic agents, for the treatment of cancer, by inhibiting the USP1 protein to enhance the effectiveness of chemotherapy, reduce tumor size, delay or prevent tumor rebound.

Benefits of technology

The composition can effectively reduce tumor size, increase tumor regression rate, reduce or inhibit tumor growth, and reduce the toxicity and adverse reactions of chemotherapeutic agents, delay or prevent tumor rebound.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013018A_ABST
    Figure CN119013018A_ABST
Patent Text Reader

Abstract

The present disclosure provides a composition comprising (i) a chemotherapeutic agent and (ii) an ubiquitin-specific processing protease 1 (USP1) inhibitor of formula I: (I): # imgabs0 #, or a pharmaceutically acceptable salt or solvate thereof. The present disclosure also relates to methods of treating cancer, delaying, reducing and / or preventing tumor rebound comprising administering the provided composition.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application Nos. 63 / 380,735 (filed on October 24, 2022) and 63 / 329,228 (filed on April 8, 2022), each of which is incorporated herein by reference in its entirety. Citation of a sequence listing submitted electronically via EFS-WEB

[0002] The contents of the electronically submitted sequence listing (name 4195_025PC03_Seqlisting_ST26.txt; size: 2,997 bytes; creation date: April 6, 2023) are incorporated herein by reference in their entirety. Technical Field

[0003] The present disclosure provides a composition of a chemotherapeutic agent and an inhibitor of ubiquitin-specific processing protease 1 (USP1). Provided is a method for treating cancer, delaying, reducing and / or preventing tumor rebound, comprising administering the composition. Background Art

[0004] Ubiquitin is a small (76 amino acid) protein that is attached to target proteins after transcription. The outcome of ubiquitination is determined by the number and bond topology of the ubiquitin molecules conjugated to the target protein. For example, proteins exhibiting lysine 48-linked polyubiquitin chains are generally targeted to the proteasome for degradation, while monoubiquitination or polyubiquitin chains linked through other lysines regulate non-proteolytic functions such as cell cycle regulation, DNA damage repair, transcription, and endocytosis. Ubiquitination is a reversible process, and enzymes called deubiquitinases remove ubiquitin from target proteins.

[0005] USP1 is a deubiquitinase that plays a role in DNA damage repair. USP1 interacts with UAF1 (USP1-associated factor 1) to form a complex that is required for deubiquitinase activity. The USP1 / UAF1 complex deubiquitinates monoubiquitinated PCNA (proliferating cell nuclear antigen) and monoubiquitinated FANCD2 (Fanconianemia complementation group D2), proteins with important functions in the translesion synthesis (TLS) and Fanconi anemia (FA) pathways, respectively. The USP1 / UAF1 complex also deubiquitinates Fanconi anemia complementation group I (FANCI). Both pathways are essential for repairing DNA damage induced by DNA cross-linking agents such as cisplatin and mitomycin C (MMC).

[0006] Chemotherapeutic agents induce a variety of different DNA lesions that cells must recognize and resist in order to survive. Chemotherapeutic agents can be divided into several categories based on their mechanism of action and the type of damage they cause, but there is considerable overlap between the different categories. Alkylating agents directly modify DNA and typically induce a large amount of DNA damage that is repaired via the nucleotide excision repair pathway (NER). Platinum drugs also induce a large amount of DNA damage that is repaired via the NER pathway and are effective in treating a variety of cancers. A large class of drugs targets DNA metabolism and includes DNA intercalating agents, topoisomerase poisons, and antimetabolites. Many chemotherapeutic agents cause damage to DNA that results in DNA adducts, strand breaks, or DNA replication fork stalling / collapse, and homologous recombination (HR) and Fanconi anemia proteins are often required to repair or restart these lesions.

[0007] There remains an unmet medical need for more effective cancer treatments, such as combination therapies. Summary of the invention

[0008] Provided herein are combinations of (i) an inhibitor of ubiquitin-specific processing protease 1 (USP1) and (ii) a chemotherapeutic agent. Also provided herein are methods of using such compositions to treat cancer patients.

[0009] In one aspect, the present disclosure relates to a composition comprising (i) a chemotherapeutic agent and (ii) an ubiquitin-specific processing protease 1 (USP1) inhibitor, wherein the USP1 inhibitor is a compound having Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein: X 1 and X 2 Each independently selected from N and CR 2 ; R 1 and R 2 are each independently selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; R 3 is optionally substituted phenyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyrazinyl, optionally substituted pyridazinyl or optionally substituted pyrazolyl; X 11 and X 12 are each independently selected from N and CH; R 5′ is selected from hydrogen, optionally substituted (C 1 -C 6 ) alkyl, optionally substituted (C 2 -C6 )alkenyl, optionally substituted (C 2 -C 6 )alkynyl, optionally substituted (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, (C 1 -C 6 ) hydroxyalkyl, cyano, halogen, sulfonamide, -C(=O)R 23 、-C(=O)OR 24 、-NR 32a R 32b 、-NR 31a C(=O)R 25 、-NR 31a C(=O)NR 31a R 31b 、-C(=O)NR 31a R 31b 、-S(O) 2 R 27 、-NR 31a SO 2 R 27 , optionally substituted (C 6 -C 14 ) aryl, optionally substituted (C 6 -C 14 )Fang-(C 1 -C 2 )alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl-(C 1 -C 2 ) alkyl, optionally substituted (C 3 -C 8 )cycloalkyl, optionally substituted ((C 3 -C 8 )cycloalkyl)-(C 1 -C 2 )alkyl, optionally substituted heterocyclic, optionally substituted heterocyclic-(C 1 -C 2 )alkyl, optionally substituted-O-(C 6 -C 14 )aryl, optionally substituted -O-(C 6 -C 14 )Fang-(C 1 -C 2 )alkyl, optionally substituted -O-heteroaryl, optionally substituted -O-heteroaryl-(C 1 -C 2)alkyl, optionally substituted-O-(C 3 -C 8 )cycloalkyl, optionally substituted-O-((C 3 -C 8 )cycloalkyl)-(C 1 -C 2 )alkyl, optionally substituted -O-heterocyclic, optionally substituted -O-heterocyclic-(C 1 -C 2 )alkyl; R 5 Selected from optionally substituted (C 1 -C 6 ) alkyl, optionally substituted (C 2 -C 6 )alkenyl, optionally substituted (C 2 -C 6 )alkynyl, optionally substituted (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, (C 1 -C 6 ) hydroxyalkyl, cyano, halogen, sulfonamide, -C(=O)R 23 、-C(=O)OR 24 、-NR 32a R 32b 、-NR 31a C(=O)R 25 、-NR 31a C(=O)NR 31a R 31b 、-C(=O)NR 31a R 31b 、-S(O) 2 R 27 、-NR 31a SO 2 R 27 , optionally substituted (C 6 -C 14 ) aryl, optionally substituted (C 6 -C 14 )Fang-(C 1 -C 2 )alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl-(C 1 -C 2 ) alkyl, optionally substituted (C 3 -C 8 )cycloalkyl, optionally substituted ((C 3-C 8 )cycloalkyl)-(C 1 -C 2 )alkyl, optionally substituted heterocyclic, optionally substituted heterocyclic-(C 1 -C 2 )alkyl, optionally substituted-O-(C 6 -C 14 )aryl, optionally substituted -O-(C 6 -C 14 )Fang-(C 1 -C 2 )alkyl, optionally substituted -O-heteroaryl, optionally substituted -O-heteroaryl-(C 1 -C 2 )alkyl, optionally substituted-O-(C 3 -C 8 )cycloalkyl, optionally substituted-O-((C 3 -C 8 )cycloalkyl)-(C 1 -C 2 )alkyl, optionally substituted -O-heterocyclic, optionally substituted -O-heterocyclic-(C 1 -C 2 ) alkyl; or R on adjacent atoms 5 One of them and R 5′ One of them and the atoms to which they are attached together form an optionally substituted (C 6 -C 14 ) aromatic ring; or one of R5 on adjacent atoms and R 5′ One of them and the atoms to which they are attached together form an optionally substituted heteroaryl ring; or R on adjacent atoms 5 One of them and R 5′ One of them and the atoms to which they are attached together form an optionally substituted (C 3 -C 8 ) cycloalkyl ring; or R on an adjacent atom 5 One of them and R 5′ One of them and the atoms to which they are attached together form an optionally substituted heterocycloalkyl ring; or R on adjacent atoms 5 One of them and R 5′ or R on adjacent atoms together form an optionally substituted spirocycloalkyl ring on the same atom to which they are attached; 5′ One of them and R 5 One of the forms taken together at the same atom to which they are attached forms an optionally substituted spiroheterocycloalkyl ring; R 6 and R 7are each independently selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; R 23 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, amino, alkylamino, dialkylamino, cycloalkylamino, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkylamino)alkyl, (cycloalkyl)alkyl, aralkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, (amino)(hydroxy)alkyl, (aralkylamino)alkyl, optionally substituted heterocyclo, optionally substituted heteroaryl, optionally substituted aryl, and optionally substituted cycloalkyl; R 31a and R 31b are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, alkoxyalkyl, cycloalkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, aralkyl, and (heteroaryl)alkyl; and R 24 , R 25 , R 27 , R 32a and R 32b each is independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, amino, alkylamino, dialkylamino, cycloalkylamino, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkylamino)alkyl, (cycloalkyl)alkyl, aralkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, (amino)(hydroxy)alkyl, (aralkylamino)alkyl, alkoxyalkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted aryl, and optionally substituted cycloalkyl.

[0010] In one aspect, the chemotherapeutic agent is a platinum, a monofunctional alkylating agent, a difunctional alkylating agent, an antimetabolite, a topoisomerase inhibitor, or a combination thereof.

[0011] In another aspect, the chemotherapeutic agent is a platinum selected from the group consisting of cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, nedaplatin and triplatin. In another aspect, the chemotherapeutic agent is cisplatin or carboplatin.

[0012] In another aspect, the chemotherapeutic agent is a monofunctional alkylating agent selected from the group consisting of alkyl sulfonates, nitrosoureas, and temozolomide; or a bifunctional alkylating agent selected from the group consisting of nitrogen mustards and mitomycin C.

[0013] In another aspect, the chemotherapeutic agent is an antimetabolite selected from gemcitabine, 5-fluorouracil, a thiopurine, and a folate analog.

[0014] In another aspect, the chemotherapeutic agent is a topoisomerase inhibitor selected from the group consisting of camptothecins, anthracyclines, and etoposide.

[0015] In another aspect, the chemotherapeutic agent comprises a combination of folinate, 5-fluorouracil, and oxaliplatin.

[0016] In one aspect, the disclosure relates to a method of treating cancer in a subject comprising administering such a composition as described in the preceding aspects.

[0017] In another aspect, the present disclosure relates to a method of delaying, reducing and / or preventing tumor rebound in a subject, comprising administering such a composition as described in the preceding aspects.

[0018] In one aspect, the present disclosure relates to use of the composition in the manufacture of a medicament for treating cancer.

[0019] In another aspect, the present disclosure relates to a pharmaceutical composition comprising the combination and a pharmaceutically acceptable carrier.

[0020] In one aspect, the pharmaceutical composition is used to treat cancer.

[0021] In one aspect, the present disclosure relates to a kit comprising the composition or the pharmaceutical composition, and instructions for administering the composition to a subject having cancer.

[0022] In one aspect, the USP1 inhibitor has one of the following structures: or a pharmaceutically acceptable salt or solvate thereof, wherein X 1 and X 2 Each independently selected from N and CR 2 ; R 1 is selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; R 5 for: X 6 Selected from NR 13 and CR 18 ; X 7 Selected from NR 14 and CR 19 ; X 8 Selected from NR 15 and CR 20 ; X9 Selected from NR 16 and CR 21 ; X 10 Selected from NR 17 and CR 22 ; R 13 , R 14 , R 15 , R 16 and R 17 each is absent or is independently selected from hydrogen, halogen, methyl, ethyl, isopropyl, cyclopropyl, methoxy, triazolyl, cyano, optionally substituted alkyl, amino, alkylamino, dialkylamino, difluoromethyl, trifluoromethyl, methylsulfonyl, and methylazetidinyl; and R 18 , R 19 , R 20 , R 21 and R 22 each independently selected from hydrogen, halogen, methyl, ethyl, isopropyl, cyclopropyl, methoxy, triazolyl, cyano, optionally substituted alkyl, amino, alkylamino, dialkylamino, difluoromethyl, trifluoromethyl, methylsulfonyl and methylazetidinyl; R 6 and R 7 are each independently selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; and R 8 , R 9 and R 11 each independently selected from hydrogen, halogen, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, heteroaryloxy, aralkylaralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, carboxyl, carboxylalkyl, alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, alkoxyalkyl, (amino)alkyl, hydroxyalkylamino, (alkylamino)alkyl, (dialkylamino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclyl)alkyl, (cycloalkylamino)alkyl, (C 1-4 haloalkoxy)alkyl or (heteroaryl)alkyl.

[0023] In another aspect, the USP1 inhibitor is a compound selected from the group consisting of: (a) Compound 1: (b) Compound 2: (c) Compound 3: and pharmaceutically acceptable salts, hydrates, solvates, amorphous solids or polymorphs thereof. In another aspect, Compound 1, Compound 2 or Compound 3 is provided in the form of a co-crystal. In other aspects, Compound 1, Compound 2 or Compound 3 is provided in the form of a co-crystal with a pharmaceutically acceptable acid.

[0024] In one aspect, the USP1 inhibitor is Compound 1, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid or polymorph thereof. In another aspect, Compound 1 is provided in the form of a co-crystal with a pharmaceutically acceptable acid. In one aspect, the USP1 inhibitor is a co-crystal of Compound 1 and gentisic acid, i.e., a co-crystal of gentisic acid and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine.

[0025] In another aspect, the USP1 inhibitor is Compound 2, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid or polymorph thereof. In another aspect, Compound 2 is provided in the form of a co-crystal with a pharmaceutically acceptable acid.

[0026] In another aspect, the USP1 inhibitor is Compound 3, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid or polymorph thereof. In another aspect, Compound 3 is provided in the form of a co-crystal with a pharmaceutically acceptable acid.

[0027] In another aspect, the USP1 inhibitor is the gentisate salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine.

[0028] In one aspect, the subject is a mammal. In another aspect, the mammal is a human.

[0029] In one aspect, the subject's cancer cells are homologous recombination repair (HRR) positive.

[0030] In one aspect, the cancer or tumor is an advanced solid tumor. In one aspect, the cancer or tumor is selected from the group consisting of lung cancer, non-small cell lung cancer (NSCLC), colon cancer, bladder cancer, osteosarcoma, ovarian cancer, skin cancer, uterine cancer, peritoneal cancer, endometrial cancer, pancreatic cancer, gastric cancer, bile duct cancer and breast cancer.

[0031] In one aspect, the chemotherapeutic agent and the USP1 inhibitor are administered sequentially. In another aspect, the chemotherapeutic agent and the USP1 inhibitor are administered simultaneously.

[0032] In one aspect, the USP1 inhibitor and the chemotherapeutic agent are provided in separate dosage forms. In another aspect, the USP1 inhibitor is provided in an oral dosage form. In another aspect, the chemotherapeutic agent is provided in an injectable dosage form. In another aspect, the chemotherapeutic agent is provided in an oral dosage form.

[0033] In one aspect, the chemotherapeutic agent and the USP1 inhibitor are administered in therapeutically effective amounts sufficient to produce one or more therapeutic effects selected from the group consisting of (i) reduction in tumor size, (ii) increase in tumor regression rate, and (iii) reduction or inhibition of tumor growth.

[0034] In another aspect, the chemotherapeutic agent and the USP1 inhibitor delay, reduce and / or prevent tumor rebound.

[0035] In one aspect, the USP1 inhibitor, gemcitabine, and carboplatin are administered. In another aspect, the subject has ovarian cancer, triple negative breast cancer, or non-small cell lung cancer.

[0036] In one aspect, the USP1 inhibitor, folinate, 5-fluorouracil, and oxaliplatin are administered. In another aspect, the subject has colorectal cancer, pancreatic cancer, bile duct cancer, esophageal cancer, or gastric cancer.

[0037] In one aspect, the cancer or tumor was previously treated with platinum therapy. In some aspects, the cancer or tumor is platinum-resistant or platinum-refractory. In one aspect, the platinum therapy is selected from the group consisting of cisplatin, carboplatin, oxaliplatin, and combinations thereof.

[0038] In one aspect, the chemotherapeutic agent and the USP1 inhibitor are administered in amounts effective to reduce unacceptable toxicity and / or unacceptable adverse effects of the chemotherapeutic agent administered as a monotherapy.

[0039] In one aspect, the present disclosure relates to a composition for treating cancer. In another aspect, the present disclosure relates to the use of such a composition in the preparation of a medicament for treating cancer. In one aspect, the cancer is an advanced solid tumor. In one aspect, the cancer is selected from the group consisting of lung cancer, non-small cell lung cancer (NSCLC), colon cancer, bladder cancer, osteosarcoma, ovarian cancer, skin cancer, uterine cancer, peritoneal cancer, endometrial cancer, pancreatic cancer, gastric cancer, bile duct cancer, and breast cancer. In one aspect, the cancer has been previously treated with platinum therapy. In one aspect, the cancer or tumor is platinum-resistant or platinum-refractory. In one aspect, the platinum therapy is selected from the group consisting of cisplatin, carboplatin, oxaliplatin, and combinations thereof.

[0040] Additional aspects and advantages of the present disclosure will be set forth in part in the following description and will result from the description, or may be learned by practicing the present disclosure. The aspects and advantages of the present disclosure will be realized and obtained by means of the elements and combinations particularly pointed out in the appended claims.

[0041] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] FIG. 1(A) shows the tolerability of 4 mg / kg cisplatin combined with Compound (1)-gentisic acid co-crystal in non-tumor bearing female Balb / c nude mice.

[0043] FIG. 1(B) shows the survival rate of 4 mg / kg cisplatin combined with Compound (1)-gentisic acid co-crystal in non-tumor bearing female Balb / c nude mice.

[0044] FIG. 2(A) shows the tolerability of 5 mg / kg cisplatin combined with Compound (1)-gentisic acid co-crystal in non-tumor bearing female Balb / c nude mice.

[0045] FIG. 2(B) shows the survival rate of 5 mg / kg cisplatin combined with Compound (1)-gentisic acid co-crystal in non-tumor bearing female Balb / c nude mice.

[0046] FIG. 3(A) shows the tolerability of 6 mg / kg cisplatin combined with Compound (1)-gentisic acid co-crystal in non-tumor bearing female Balb / c nude mice.

[0047] FIG3(B) shows the survival rate of 6 mg / kg cisplatin combined with Compound (1)-gentisic acid co-crystal in non-tumor bearing female Balb / c nude mice.

[0048] Figure 4 An XRPD pattern corresponding to crystalline Form 2 is shown.

[0049] Figure 5 The DSC and TGA thermograms corresponding to crystalline Form 2 are shown.

[0050] FIG. 6(A) shows the changes in tumor volume in female NOD SCID mice bearing MDA-MB-436 tumors after treatment with 2 mg / kg cisplatin combined with 100 mg / kg compound (1)-gentisic acid co-crystal.

[0051] FIG. 6(B) shows the tolerability of 2 mg / kg cisplatin combined with 100 mg / kg Compound (1)-gentisic acid co-crystal in female NOD SCID mice bearing MDA-MB-436 tumors.

[0052] FIG. 7(A) shows the changes in tumor volume of 5 mg / kg cisplatin combined with 100 mg / kg compound (1)-gentisic acid cocrystal in female athymic nude mice bearing HBCx-8 tumors.

[0053] FIG. 7(B) shows the tolerability of 5 mg / kg cisplatin combined with 100 mg / kg Compound (1)-gentisic acid co-crystal in female athymic nude mice bearing HBCx-8 tumors.

[0054] FIG8(A) shows the changes in tumor volume of 3 mg / kg cisplatin combined with 100 mg / kg compound (1)-gentisic acid co-crystal in female athymic nude mice bearing HBCx-8 tumors.

[0055] FIG8(B) shows the tolerability of 3 mg / kg cisplatin combined with 100 mg / kg Compound (1)-gentisic acid co-crystal in female athymic nude mice bearing HBCx-8 tumors. DETAILED DESCRIPTION

[0056] One aspect of the present disclosure is based on the use of a combination of (i) a chemotherapeutic agent and (ii) an inhibitor of ubiquitin-specific processing protease 1 (USP1). The combination can be used to inhibit USP1 protein and to treat diseases, disorders or conditions responsive to chemotherapeutic agents and / or inhibition of USP1 protein, such as cancer.

[0057] In some aspects, the combination of a USP1 inhibitor and a chemotherapeutic agent provides a synergistic effect.

[0058] In some aspects, the USP1 inhibitor and the chemotherapeutic agent are in a therapeutically effective amount sufficient to produce a therapeutic effect comprising: (i) reducing tumor size; (ii) increasing the rate of cancer tumor regression; (iii) reducing or inhibiting cancer tumor growth; and / or (iv) reducing the toxic effects of the chemotherapeutic agent administered as a monotherapy. In some aspects, the USP1 inhibitor and the chemotherapeutic agent can delay, reduce or prevent tumor rebound (rapid regrowth). definition

[0059] All technical and scientific terms used herein have the same meaning as those commonly understood by those of ordinary skill in the art of the present disclosure. In the event of a conflict, the present application, including definitions, will prevail. In addition, unless the context otherwise requires, singular terms will include the plural and plural terms will include the singular. All publications, patents, and other references mentioned herein are incorporated by reference in their entirety for all purposes, as if each separate publication or patent application was specifically and individually indicated to be incorporated by reference.

[0060] Although methods and materials similar or equivalent to those described herein can be used to practice or test the present disclosure, suitable methods and materials are described below. Materials, methods and examples are merely exemplary and are not intended to be limiting. Other features and advantages of the present disclosure will be apparent from the following detailed description and claims.

[0061] To further define the present disclosure, the following terms and definitions are provided.

[0062] It should be understood that the embodiments described herein include "consisting of" and / or "consisting essentially of". As used herein, the singular forms "a / an", "a / an", and "the" include plural references unless otherwise indicated. The use of the term "or" herein does not mean that the alternatives are mutually exclusive.

[0063] In this application, unless explicitly stated or understood by one skilled in the art, the use of "or" means "and / or." In the context of multiple dependent claims, the use of "or" refers back to more than one of the preceding independent or dependent claims.

[0064] The term "and / or" when used herein is considered to specifically disclose each of the two specified features or components, with or without the other. Thus, the term "and / or" in a phrase such as "A and / or B" is intended to include "A and B" or "A or B", "A" (alone) and "B" (alone). Likewise, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to cover each of the following: A, B, and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0065] As used herein, the term "about" includes ±10% of the number being recited. Thus, "about 10" means 9 to 11. As will be understood by those skilled in the art, references herein to "about" a value or parameter include (and describe) the value or parameter itself. For example, a description of "about X" includes a description of "X".

[0066] As used herein, "treatment" is a method for obtaining a beneficial or desired clinical result. As used herein, "treatment" encompasses any administration or application of a therapeutic agent for a disease in a mammal including a human. For the purposes of this disclosure, a beneficial or desired clinical result includes, but is not limited to, any one or more of the following: alleviating one or more symptoms, reducing the extent of the disease, preventing or delaying disease spread (e.g., metastasis), preventing or delaying disease recurrence, delaying or slowing disease progression, improving the disease condition, inhibiting disease or disease progression, inhibiting or slowing the disease or its progress, preventing its development and symptom relief (whether in part or in its entirety). "Treatment" also encompasses the pathological results of reducing proliferative diseases. The methods provided herein encompass any one or more of these therapeutic aspects. As described above, the term treatment does not require 100% removal of all aspects of the disease.

[0067] In the context of cancer, the term "treat" includes, but is not limited to, inhibiting cancer cell growth, inhibiting cancer cell replication, reducing overall tumor burden, and delaying, halting or slowing tumor growth, progression or metastasis.

[0068] As used herein, "delay" means to postpone, delay, slow, arrest, stabilize, inhibit and / or postpone the development or progression of a disease (e.g., cancer). The delay may have varying lengths of time, depending on the medical history and / or individual being treated.

[0069] A "therapeutically effective amount" of a substance may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the substance to elicit a desired response in the individual. A therapeutically effective amount is also an amount in which any toxic or adverse effects of the substance are outweighed by the therapeutically beneficial effects. A therapeutically effective amount may be delivered in one or more administrations. A therapeutically effective amount refers to an amount effective to achieve the desired therapeutic effect at the necessary dosage and time period.

[0070] As used herein, the terms "combination", "therapeutic combination", "combination composition", "combination therapy" or "pharmaceutical composition" may include a fixed combination in one unit dosage form, separate dosage units or kit of parts or instructions for combined administration, wherein the USP1 inhibitor and the chemotherapeutic agent may be administered simultaneously and independently or separately within a time interval. The combined pharmaceutical composition may be suitable for simultaneous, separate or sequential administration.

[0071] Combination therapy can provide and prove to be "synergistic", that is, the effect achieved when the active ingredients used together exceed the sum of the effects caused by the use of the compounds separately. A synergistic effect can include a significant reduction in the effective dose of the combination of the two active ingredients compared to the effective dose of each active ingredient when administered separately. A synergistic effect can also include a reduction in the toxicity of the combination of the two active ingredients compared to the toxicity of each active ingredient when administered separately. A synergistic effect can also apply an effect that cannot be achieved by any of the active ingredients as a single agent. A synergistic effect can include, but is not limited to, an effect of treating cancer by reducing tumor size, inhibiting tumor growth, or increasing the survival rate of a subject. A synergistic effect can also include reducing cancer cell viability, inducing cancer cell death, and inhibiting or delaying cancer cell growth. For example, a synergistic effect can be achieved when the active ingredients are: (1) co-formulated and administered or delivered simultaneously in a combined unit dosage formulation; (2) delivered continuously, alternatingly, or in parallel as separate formulations; or (3) by some other regimen. When delivered in alternation therapy, a synergistic effect can be achieved when the compounds are administered or delivered sequentially.

[0072] Determination of synergistic interactions between USP1 inhibitors and chemotherapeutic agents can be based on the results obtained from the assays described herein. For example, the Bliss independence model can be used to evaluate the combined effect. The Bliss score quantifies the degree of enhancement relative to a single agent, and a Bliss score>0 indicates more than just additivity. In some aspects, a Bliss score of more than 10 indicates a strong synergistic effect. In other aspects, a score of 6 or greater indicates a synergistic effect. In some aspects, the Bliss score is about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, or about 25.

[0073] As used herein, "homologous recombination deficiency score" or "HRD score" refers to an algorithmic assessment of three measures of tumor genomic instability, namely, loss of heterozygosity, telomereal allelic imbalance, and large-scale state transitions.

[0074] The term "HRR+" refers to homologous recombination repair positive. The HRR+ status of cancer cells can be determined based on a biopsy. Homologous recombination repair is an important cellular mechanism by which double-stranded DNA breaks (DSBs) can be corrected with high fidelity. For purposes of this disclosure, HRR+, HRP, HRR-functional cells, and HRR-positive cells are used interchangeably.

[0075] The terms "administer / administering / administration" and the like refer to methods that can be used to achieve delivery of a therapeutic agent to a desired site of biological action. Administration techniques that can be used for the agents and methods described herein can be found in, for example, Goodman and Gilman, The Pharmacological Basis of Therapeutics, current edition; Pergamon; and Remington's, Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, Pa. Administration of two or more therapeutic agents includes simultaneous (concurrent) and sequential administration in any order.

[0076] The terms "pharmaceutical preparation" and "pharmaceutical composition" refer to a preparation that is in such form as to permit the biological activity of the active ingredient to be effective and does not contain additional components that are unacceptably toxic to the subject to which the preparation will be administered. Such preparations may be sterile.

[0077] As used herein, the term "pharmaceutically acceptable" refers to those compounds, substances, compositions and / or dosage forms that are, within the scope of reasonable medical judgment, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response or other problems or complications, and commensurate with a reasonable benefit / risk ratio.

[0078] The terms "pharmaceutically acceptable carrier", "pharmaceutically acceptable excipient", "physiologically acceptable carrier" or "physiologically acceptable excipient" refer to pharmaceutically acceptable materials, compositions or carriers, such as liquid or solid fillers, diluents, excipients, solvents or encapsulating materials. Pharmaceutically acceptable carriers are non-toxic to subjects at the dosages and concentrations used and are compatible with the other ingredients in the formulation. Pharmaceutically acceptable carriers are suitable for the formulation used. In certain aspects, each ingredient is "pharmaceutically acceptable", i.e., compatible with the other ingredients of the pharmaceutical formulation and suitable for use in contact with tissues or organs of humans and animals without excessive toxicity, irritation, allergic reaction, immunogenicity or other problems or complications, commensurate with a reasonable benefit / risk ratio. See Remington: The Science and Practice of Pharmacy, 21st Edition, Lippincott Williams & Wilkins: Philadelphia, PA, 2005; Handbook of Pharmaceutical Excipients, 5th Edition, Rowe et al., Eds., The Pharmaceutical Press and the American Pharmaceutical Association: 2005; and Handbook of Pharmaceutical Additives, 3rd Edition, Ash and Ash Eds., GowerPublishing Company: 2007; Pharmaceutical Preformulation and Formulation, Gibson Ed., CRC Press LLC: Boca Raton, FL, 2004 (incorporated herein by reference).

[0079] The terms "active ingredient" and "active substance" refer to a compound that is administered to a subject alone or in combination with one or more pharmaceutically acceptable excipients for the treatment, prevention or amelioration of the symptoms of one or more conditions, disorders or diseases. As used herein, "active ingredient" and "active substance" may be an optically active isomer of a compound described herein.

[0080] The terms "drug," "therapeutic agent," and "chemotherapeutic agent" refer to a compound, or pharmaceutical composition thereof, that is administered to a subject for the treatment, prevention, or amelioration of the symptoms of one or more conditions, disorders, or diseases.

[0081] The term "solvate" refers to a compound or salt thereof provided herein, which further includes a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. When the solvent is water, the solvate is a hydrate. When the solvent includes ethanol, the compound can be an ethanol solvate.

[0082] The term "anhydrous" as applied to a compound refers to the solid state of the compound that contains no structural water within the crystal lattice.

[0083] A "sterile" preparation is sterile, or substantially free of viable microorganisms and their spores.

[0084] The term "container" means any receptacle and closure therefor suitable for storing, shipping, dispensing and / or disposing of a pharmaceutical product.

[0085] The term "insert" or "package insert" means the information that accompanies a drug product and provides a description of how to administer the product as well as the safety and efficacy data necessary to allow physicians, pharmacists, and patients to make reasonable decisions about the product's use. The package insert is generally considered the "label" for the drug.

[0086] As used herein, the term "disease" or "disorder" or "condition" refers to a condition for which treatment is needed and / or desired, and refers to a disorder and / or abnormality that is generally regarded as a pathological condition or function and that may manifest itself in the form of specific signs, symptoms and / or dysfunction. As demonstrated below, the combination of the disclosed USP1 inhibitors and chemotherapeutic agents can be used to treat diseases and conditions in which inhibition of the chemotherapeutic agent and / or USP1 protein provides a benefit, such as proliferative diseases.

[0087] As used herein, "USP1" and "ubiquitin-specific processing protease 1" refer to any native polypeptide or polynucleotide encoding USP1. The term "USP1" encompasses "full-length," unprocessed USP1 polypeptides, as well as any form of USP1 resulting from processing within the cell (e.g., removal of the signal peptide). The term also encompasses naturally occurring variants of USP1, such as variants encoded by splice variants and allelic variants. The USP1 polypeptides described herein can be isolated from a variety of sources, such as from a human tissue type or from another source, or prepared by recombinant or synthetic methods. Human USP1 sequences are known, including, for example, sequences publicly available as UniProt No. 094782 (including isoforms). As used herein, the term "human USP1 protein" refers to a USP1 protein comprising the amino acid sequence shown in SEQ ID NO: 1:

[0088] USP1 is a deubiquitinase that acts as part of a complex with UAF1. The "deubiquitinase activity" of USP1 includes its ability to deubiquitinate as part of the USP1-UAF1 complex.

[0089] The term "reduction" or "reduce" or "inhibition" refers to a reduction or cessation of any phenotypic characteristic, or a reduction or cessation of the incidence, degree or likelihood of the characteristic. "Reduction" or "inhibition" refers to a decrease, reduction or prevention of activity, function and / or amount compared to a reference. In some aspects, "reduction" or "inhibition" means being able to cause an overall reduction of 20% or greater. In some aspects, "reduction" or "inhibition" means being able to cause an overall reduction of 50% or greater. In some aspects, "reduction" or "inhibition" means being able to cause an overall reduction of 75%, 85%, 90%, 95% or greater. In some aspects, the amount indicated above is inhibited or reduced over a period of time relative to a control over the same period of time.

[0090] In some aspects, inhibition of USP1 protein is inhibition of one or more activities or functions of USP1 protein. It should be understood that the activities or functions of one or more USP1 proteins can be inhibited in vitro or in vivo. Non-limiting examples of activities and functions of USP1 include deubiquitinase activity and formation of a complex with UAF1, and as described herein. Exemplary levels of inhibition of the activity of one or more USP1 proteins include at least 10% inhibition, at least 20% inhibition, at least 30% inhibition, at least 40% inhibition, at least 50% inhibition, at least 60% inhibition, at least 70% inhibition, at least 80% inhibition, at least 90% inhibition, and up to 100% inhibition.

[0091] The terms "individual" or "subject" are used interchangeably herein and refer to an animal, such as a mammal, such as a human. In some cases, methods for treating mammals are provided, including, but not limited to, humans, rodents, apes, felines, canines, equines, bovines, porcines, sheep, goats, mammalian laboratory animals, mammalian livestock, mammalian sports animals, and mammalian pets. In some instances, an "individual" or "subject" refers to an individual in need of treatment for a disease or condition. In some cases, the subject being treated may be a patient, meaning that the subject has been identified as suffering from a condition associated with the treatment, or is at a particular risk of contracting the condition.

[0092] As used herein, the terms "cancer" and "tumor" refer to or describe a physiological condition in a mammal characterized by unregulated cell growth in a cell population. The term encompasses solid and hematologic cancers / lymphomas. Examples of cancer include, but are not limited to, cancers with defects in the DNA damage repair pathway. Additional examples of cancer include, but are not limited to, ovarian cancer, breast cancer (including triple-negative breast cancer), non-small cell lung cancer (NSCLC), and osteosarcoma. The cancer may be BRCA1 or BRCA2 wild-type. The cancer may also be a BRCA1 or BRCA2 mutant. The cancer may also be a chemotherapeutic resistant or refractory cancer, or a chemotherapeutic resistant or refractory BRCA1 or BRCA2 mutant cancer. The cancer may be BARD1 wild-type. The cancer may also be a BARD1 mutant. The cancer may be BRIP1 wild-type. The cancer may also be a BRIP1 mutant. The cancer may be FANCA wild-type. The cancer may also be a FANCA mutant. The cancer may be NBN wild-type. The cancer may also be a NBN mutant. The cancer may be PALB2 wild-type. The cancer may also be a PALB2 mutant. Cancer can be RAD51 wild type. Cancer can also be RAD51 mutant. Cancer can be RAD51B wild type. Cancer can also be RAD51B mutant. Cancer can be RAD51C wild type. Cancer can also be RAD51C mutant. Cancer can be RAD51D wild type. Cancer can also be RAD51D mutant.

[0093] In one aspect, the cancer is a homologous recombination DNA repair-positive (HRR+ or HRP) cancer. The combination of the chemotherapeutic agent and the USP1 inhibitor of the present disclosure provides better effects / results in HRR+ cancer cells. Homologous recombination DNA repair (HRR) is an important mechanism for repairing DNA damage. Homologous recombination DNA repair is a process in which double-stranded DNA breaks and interstrand crosslinks use sister chromatids as repair templates. DNA damage can be removed error-free by this mechanism. In addition, during DNA replication, the HRR pathway supports the recovery of stalled replication forks. Curtin, N, Nature Reviews / Cancer 12: 801-817 (2012); Creeden et al., BMC Cancer 21: 1154 (2021) and Scott et al., Oncotarget 12 (16): 1600-1614 (2021).

[0094] As used herein, the term "loss of function" mutation refers to a mutation that causes gene deficiency, reduced gene expression, or the production of a gene product (e.g., protein) with reduced activity or inactivity. Loss of function mutations include, for example, missense mutations, nucleotide insertions, nucleotide deletions, and gene deletions. Loss of function mutations also include dominant negative mutations. Therefore, cancer cells with a loss of function mutation in a gene encoding p53 include cancer cells containing missense mutations in a gene encoding p53 and cancer cells lacking a gene encoding p53. I. USP1 inhibitors

[0095] USP 1 inhibitors have been disclosed, for example, in WO 2020 / 132269 and WO 2022 / 094096, each of which is incorporated herein by reference in its entirety.

[0096] In some aspects, the ubiquitin-specific processing protease 1 (USP1) inhibitors of the present disclosure have Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein: X 1 and X 2 Each independently selected from N and CR 2 ; R 1 and R 2 are each independently selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; R 3 is optionally substituted phenyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyrazinyl, optionally substituted pyridazinyl or optionally substituted pyrazolyl; X 11 and X 12 are each independently selected from N and CH; R 5′ is selected from hydrogen, optionally substituted (C 1 -C 6 ) alkyl, optionally substituted (C 2 -C 6 )alkenyl, optionally substituted (C 2 -C 6 )alkynyl, optionally substituted (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, (C 1 -C 6) hydroxyalkyl, cyano, halogen, sulfonamide, -C(=O)R 23 、-C(=O)OR 24 、-NR 32a R 32b 、-NR 31a C(=O)R 25 、-NR 31a C(=O)NR 31a R 31b 、-C(=O)NR 31a R 31b 、-S(O) 2 R 27 、-NR 31a SO 2 R 27 , optionally substituted (C 6 -C 14 ) aryl, optionally substituted (C 6 -C 14 )Fang-(C 1 -C 2 )alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl-(C 1 -C 2 ) alkyl, optionally substituted (C 3 -C 8 )cycloalkyl, optionally substituted ((C 3 -C 8 )cycloalkyl)-(C 1 -C 2 )alkyl, optionally substituted heterocyclic, optionally substituted heterocyclic-(C 1 -C 2 )alkyl, optionally substituted-O-(C 6 -C 14 )aryl, optionally substituted -O-(C 6 -C 14 )Fang-(C 1 -C 2 )alkyl, optionally substituted -O-heteroaryl, optionally substituted -O-heteroaryl-(C 1 -C 2 )alkyl, optionally substituted-O-(C 3 -C 8 )cycloalkyl, optionally substituted-O-((C 3 -C 8 )cycloalkyl)-(C 1 -C 2 )alkyl, optionally substituted -O-heterocyclic, optionally substituted -O-heterocyclic-(C 1 -C 2 )alkyl; R 5 Selected from optionally substituted (C 1 -C 6 ) alkyl, optionally substituted (C 2 -C 6 )alkenyl, optionally substituted (C 2 -C 6 )alkynyl, optionally substituted (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, (C 1 -C 6 ) hydroxyalkyl, cyano, halogen, sulfonamide, -C(=O)R 23 、-C(=O)OR 24 、-NR 32a R 32b 、-NR 31a C(=O)R 25 、-NR 31a C(=O)NR 31a R 31b 、-C(=O)NR 31a R 31b 、-S(O) 2 R 27 、-NR 31a SO 2 R 27 , optionally substituted (C 6 -C 14 ) aryl, optionally substituted (C 6 -C 14 )Fang-(C 1 -C 2 )alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl-(C 1 -C 2 ) alkyl, optionally substituted (C 3 -C 8 )cycloalkyl, optionally substituted ((C 3 -C 8 )cycloalkyl)-(C 1 -C 2 )alkyl, optionally substituted heterocyclic, optionally substituted heterocyclic-(C 1 -C 2 )alkyl, optionally substituted-O-(C 6 -C 14 )aryl, optionally substituted -O-(C 6 -C 14 )Fang-(C1 -C 2 )alkyl, optionally substituted -O-heteroaryl, optionally substituted -O-heteroaryl-(C 1 -C 2 )alkyl, optionally substituted-O-(C 3 -C 8 )cycloalkyl, optionally substituted-O-((C 3 -C 8 )cycloalkyl)-(C 1 -C 2 )alkyl, optionally substituted -O-heterocyclic, optionally substituted -O-heterocyclic-(C 1 -C 2 ) alkyl; or R on adjacent atoms 5 One of them and R 5′ One of them and the atoms to which they are attached together form an optionally substituted (C 6 -C 14 ) aromatic ring; or one of R5 on adjacent atoms and R 5′ One of them and the atoms to which they are attached together form an optionally substituted heteroaryl ring; or R on adjacent atoms 5 One of them and R 5′ One of them and the atoms to which they are attached together form an optionally substituted (C 3 -C 8 ) cycloalkyl ring; or R on an adjacent atom 5 One of them and R 5′ One of them and the atoms to which they are attached together form an optionally substituted heterocycloalkyl ring; or R on adjacent atoms 5 One of them and R 5′ or R on adjacent atoms together form an optionally substituted spirocycloalkyl ring on the same atom to which they are attached; 5′ One of them and R 5 One of the forms taken together at the same atom to which they are attached forms an optionally substituted spiroheterocycloalkyl ring; R 6 and R 7 are each independently selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; R 23is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, amino, alkylamino, dialkylamino, cycloalkylamino, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkylamino)alkyl, (cycloalkyl)alkyl, aralkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, (amino)(hydroxy)alkyl, (aralkylamino)alkyl, optionally substituted heterocyclo, optionally substituted heteroaryl, optionally substituted aryl, and optionally substituted cycloalkyl; R 31a and R 31b are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, alkoxyalkyl, cycloalkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, aralkyl, and (heteroaryl)alkyl; and R 24 , R 25 , R 27 , R 32a and R 32b each is independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, amino, alkylamino, dialkylamino, cycloalkylamino, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkylamino)alkyl, (cycloalkyl)alkyl, aralkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, (amino)(hydroxy)alkyl, (aralkylamino)alkyl, alkoxyalkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted aryl, and optionally substituted cycloalkyl.

[0097] In some aspects, the USP1 inhibitor has one of the following structures: or a pharmaceutically acceptable salt or solvate thereof, wherein X 1 and X 2 Each independently selected from N and CR 2 ; R 1 is selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; R 5 for: X 6 Selected from NR 13 and CR 18 ; X7 Selected from NR 14 and CR 19 ; X 8 Selected from NR 15 and CR 20 ; X 9 Selected from NR 16 and CR 21 ; X 10 Selected from NR 17 and CR 22 ; R 13 , R 14 , R 15 , R 16 and R 17 each is absent or is independently selected from hydrogen, halogen, methyl, ethyl, isopropyl, cyclopropyl, methoxy, triazolyl, cyano, optionally substituted alkyl, amino, alkylamino, dialkylamino, difluoromethyl, trifluoromethyl, methylsulfonyl, and methylazetidinyl; and R 18 , R 19 , R 20 , R 21 and R 22 each independently selected from hydrogen, halogen, methyl, ethyl, isopropyl, cyclopropyl, methoxy, triazolyl, cyano, optionally substituted alkyl, amino, alkylamino, dialkylamino, difluoromethyl, trifluoromethyl, methylsulfonyl and methylazetidinyl; R 6 and R 7 are each independently selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; and R 8 , R 9 and R 11 each independently selected from hydrogen, halogen, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, heteroaryloxy, aralkylaralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, carboxyl, carboxylalkyl, alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, alkoxyalkyl, (amino)alkyl, hydroxyalkylamino, (alkylamino)alkyl, (dialkylamino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclyl)alkyl, (cycloalkylamino)alkyl, (C 1-4 haloalkoxy)alkyl or (heteroaryl)alkyl.

[0098] In some aspects, the USP1 inhibitor is a compound selected from the group consisting of: (a) Compound 1: (b) Compound 2: (c) Compound 3: and pharmaceutically acceptable salts, hydrates, solvates, amorphous solids or polymorphs thereof.

[0099] In some aspects, the USP1 inhibitor is a compound selected from the group consisting of: (a) Compound 1: (b) Compound 2: (c) Compound 3: and pharmaceutically acceptable salts, hydrates, solvates, amorphous solids, polymorphs or co-crystals thereof.

[0100] The chemical name of compound 1 is 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine, as described in U.S. Publication No. US20210115049A1.

[0101] The chemical name of compound 2 is 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine, as described in U.S. Publication No. US20210115049A1.

[0102] The chemical name of compound 3 is 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine, as described in U.S. Publication No. US20210115049A1.

[0103] In one aspect, the USP1 inhibitor is Compound 1, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid, or polymorph thereof. In one aspect, the USP1 inhibitor is Compound 1, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid, polymorph, or co-crystal thereof.

[0104] In some aspects, the USP1 inhibitor for the uses and methods provided herein is a solid-state form that is a pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine (Compound 1).

[0105] In some aspects, the USP1 inhibitor for the uses and methods provided herein is in a solid state form that is a co-crystal of a pharmaceutically acceptable acid and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine (Compound 1). In some aspects, the co-crystal is composed of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine (Compound 1) and a hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, In some embodiments, the pharmaceutically acceptable acid is selected from gentisic acid, benzoic acid, salicylic acid and gallic acid. In some aspects, the pharmaceutically acceptable acid is gentisic acid.

[0106] In some aspects, the co-crystal of gentisic acid and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine (Compound 1 gentisic acid co-crystal) is in an amorphous form. In some aspects, the amorphous form is substantially free of other polymorphic forms. In some aspects, the amorphous form has a polymorphic purity of at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%.

[0107] In some aspects, the co-crystal of gentisic acid and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine (Compound 1 gentisate) is a solid state crystalline form.

[0108] In some aspects, the co-crystal of gentisic acid and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine (Compound 1 gentisic acid co-crystal) is crystalline Form 2 (Compound 1 gentisic acid co-crystal Form 2 or "Form 2"). Compound 1 gentisic acid co-crystal Form 2 is characterized by an XRPD pattern having peaks at 16.6±0.2, 18.7±0.2, and 22.5±0.2° 2θ.

[0109] In some aspects, crystalline Form 2 is a hydrate.

[0110] In some aspects, the melting point of crystalline Form 2 is from about 184° C. to about 190° C. In some aspects, the melting point of crystalline Form 2 is from about 186° C. to about 188° C. In some aspects, the melting point of crystalline Form 2 is about 187° C.

[0111] In some aspects, the crystalline form 2 is characterized by an XRPD pattern having peaks at 16.6 ± 0.2, 18.7 ± 0.2, and 22.5 ± 0.2 ° 2θ when measured under Cu Kα radiation. In another aspect, the crystalline form 2 is characterized by an XRPD pattern having peaks at 16.6 ± 0.2, 18.7 ± 0.2, 22.3 ± 0.2, and 22.5 ± 0.2 ° 2θ when measured under Cu Kα radiation. In some aspects, the crystalline form 2 is characterized by an XRPD pattern having peaks at 16.6 ± 0.2, 18.7 ± 0.2, 22.3 ± 0.2, 22.5 ± 0.2, and 26.0 ± 0.2 ° 2θ when measured under Cu Kα radiation. In some aspects, crystalline Form 2 is characterized by an XRPD pattern having peaks at 16.6±0.2, 18.7±0.2, 20.8±0.2, 22.3±0.2, 22.5±0.2, and 26.0±0.2 degrees 2-theta when measured with Cu Ka radiation.

[0112] In some aspects, crystalline Form 2 is characterized by an XRPD pattern substantially as follows Figure 4 In some aspects, the crystalline Form 2 is characterized by having three or more, four or more, five or more, or six or more XRPD peaks listed in Table 2 (a and b) below: Table 2a. Selected XRPD peaks of crystalline Form 2 Table 2b. Selected XRPD peaks of crystalline Form 2

[0113] In some aspects, the crystalline Form 2 is characterized by an internal thermal peak at about 181° C. to about 191° C., or about 183° C. to about 189° C., or about 185° C. to about 187° C. as determined by DSC. In some aspects, the crystalline Form 2 is characterized by an internal thermal peak at about 186.0° C. as determined by DSC.

[0114] In some aspects, crystalline Form 2 is characterized by a DSC curve approximately as Figure 5 shown.

[0115] In some aspects, the crystalline Form 2 is characterized by a loss of about 2.5 wt% to about 3.5 wt% between room temperature and about 170° C. In some aspects, the crystalline Form 2 is characterized by a loss of about 3.0 wt% to about 3.4 wt% between room temperature and about 170° C. In some aspects, the crystalline Form 2 is characterized by a loss of about 3.17 wt% between room temperature and about 170° C.

[0116] In some aspects, crystalline Form 2 is characterized by a TGA curve approximately as Figure 5 shown.

[0117] In some aspects, crystalline Form 2 is characterized by at least two of the following: a) Figure 4 XRPD pattern shown; b) as Figure 5 The DSC curve shown; or c) as Figure 5 TGA curve shown.

[0118] In some aspects, crystalline Form 2 has a unit cell that is indicated as monoclinic.

[0119] In some aspects, crystalline Form 2 has an a value of about b value is about and c value is about In some aspects, the crystalline form 2 has a volume of about The unit cell.

[0120] The unit cell parameters of crystalline form 2 are shown in Table 3. Table 3. Unit cell parameters of crystal form 2

[0121] In some aspects, the crystalline Form 2 is substantially free of other polymorphs. In some aspects, the polymorphic purity of the crystalline Form 2 is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.

[0122] In some aspects, the USP1 inhibitor includes a mixture comprising crystalline Form 2 and a second solid state form of Compound 1. In some aspects, the second solid state form of Compound 1 is crystalline Form A. In some aspects, the USP1 inhibitor includes a mixture comprising a majority of crystalline Form 2 compared to other solid state forms of Compound 1. Suitable solid state forms of Compound 1 are described in WO2022 / 094096, which is incorporated herein by reference.

[0123] In another aspect, the USP1 inhibitor is a solid state form of Compound 2, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid, or polymorph thereof. In another aspect, the USP1 inhibitor is a solid state form of Compound 2, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid, polymorph, or co-crystal thereof.

[0124] In some aspects, the USP1 inhibitor for the uses and methods provided herein is a solid-state form that is a pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine (Compound 2).

[0125] In some aspects, the USP1 inhibitor for the uses and methods provided herein is in a solid state form that is a co-crystal of a pharmaceutically acceptable acid and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine (Compound 2). In some aspects, the co-crystal is composed of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine (Compound 2) and a hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucose The pharmaceutically acceptable acid is selected from gentisic acid, benzoic acid, salicylic acid, and gallic acid.

[0126] Suitable solid state forms of Compound 2 are described in WO2022 / 094096, which is incorporated herein by reference.

[0127] In another aspect, the USP1 inhibitor is Compound 3, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid, or polymorph thereof. In another aspect, the USP1 inhibitor is Compound 3, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid, polymorph, or co-crystal thereof.

[0128] In some aspects, the USP1 inhibitor for the uses and methods provided herein is a solid-state form that is a pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine (Compound 3).

[0129] In some aspects, the USP1 inhibitor for the uses and methods provided herein is in a solid state form that is a co-crystal of a pharmaceutically acceptable acid and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine (Compound 3). In some aspects, the co-crystal is composed of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine (Compound 3) and a hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid. , glutamic acid, glutaric acid, glycolic acid, caproic acid, hippuric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, mucic acid, naphthalenesulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluenesulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethyl maltol, gallic acid, ethyl gallate, 4-hydroxybenzoic acid, methyl 4-hydroxybenzoate, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline and D-sorbitol. In some embodiments, the pharmaceutically acceptable acid is selected from gentisic acid, benzoic acid, salicylic acid and gallic acid.

[0130] Suitable solid-state forms of Compound 3 are described in WO2022 / 094096, which is incorporated herein by reference.

[0131] The present disclosure covers the preparation and use of salts (including non-toxic pharmaceutically acceptable salts) of USP1 inhibitors. Examples of pharmaceutically acceptable addition salts include inorganic acid and organic acid addition salts and basic salts. Pharmaceutically acceptable salts include, but are not limited to, metal salts such as sodium salts, potassium salts, cesium salts, etc.; alkaline earth metals such as calcium salts, magnesium salts, etc.; organic amine salts such as triethylamine salts, pyridine salts, methylpyridine salts, ethanolamine salts, triethanolamine salts, dicyclohexylamine salts, N, N'-diphenylmethylethylenediamine salts, etc.; inorganic acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, etc.; organic acid salts such as citrates, lactates, tartrates, maleates, fumarates, mandelates, acetates, dichloroacetates, trifluoroacetates, oxalates, formates, etc.; sulfonates such as methanesulfonates, benzenesulfonates, p-toluenesulfonates, etc.; and amino acid salts such as arginine salts, aspartates, glutamates, etc. As used herein, the term "pharmaceutically acceptable salt" refers to any salt of the USP1 inhibitor of the present disclosure that is physiologically tolerated in a target patient (eg, a mammal, such as a human), obtained, for example, by reaction with an acid or a base.

[0132] Acid addition salts can be formed by mixing a solution of a particular USP1 inhibitor with a solution of a pharmaceutically acceptable non-toxic acid, such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid, oxalic acid, dichloroacetic acid, etc. Basic salts can be formed by mixing a solution of a USP1 inhibitor of the present disclosure with a solution of a pharmaceutically acceptable non-toxic base, such as sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, etc.

[0133] In some aspects of the disclosure, a pharmaceutically acceptable salt is formed between a compound of Formula I, Formula III, Formula IV, Formula V, Formula VI, Formula Via, Compound 1, Compound 2, or Compound 3 and a pharmaceutically acceptable acid. In some aspects, the pharmaceutically acceptable acid is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, oxalic acid, fumaric acid, galactaric acid, gallic acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, caproic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, methanesulfonic acid, mucic acid, naphthalenesulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluenesulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid and vanillin. In some aspects, the pharmaceutically acceptable acid is selected from the group consisting of benzoic acid gallic acid, gentisic acid and salicylic acid.

[0134] The present disclosure encompasses the preparation and use of solvates of USP1 inhibitors. Solvates generally do not significantly change the physiological activity or toxicity of the compound and thus can serve as pharmacological equivalents. As used herein, the term "solvate" is a combination, physical association and / or solvation of a USP1 inhibitor of the present disclosure with a solvent molecule, such as a disolvate, a monosolvate or a hemisolvate, wherein the ratio of solvent molecules to the compound of the present disclosure is about 2:1, about 1:1 or about 1:2, respectively. The physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In some cases, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid, a solvate can be isolated. Therefore, "solvate" encompasses both solution-phase and separable solvates. The USP1 inhibitor of the present disclosure may exist as a solvate formed with a pharmaceutically acceptable solvent such as water, methanol, ethanol, etc., and it is intended that the present disclosure include solvated and non-solvated forms of the USP1 inhibitor of the present disclosure. One type of solvate is a hydrate. "Hydrate" refers to a specific subgroup of solvates in which the solvent molecule is water. Solvates can generally act as pharmacological equivalents. The preparation of solvates is known in the art. See, for example, M. Caira et al, J. Pharmaceut. Sci., 93(3): 601-611 (2004), which describes the preparation of a solvate of fluconazole using ethyl acetate and water. Similar preparations of solvates, hemisolvates, hydrates, etc. are described in: EC van Tonder et al., AAPS Pharm. Sci. Tech., 5(1): Article 12 (2004), and AL Bingham et al., Chem. Commun. 603-604 (2001). A typical, non-limiting method for preparing a solvate would include dissolving a USP1 inhibitor or PARP inhibitor of the present disclosure in a desired solvent (organic solvent, water, or a mixture thereof) at a temperature of greater than 20° C. to about 25° C., then cooling the solution at a rate sufficient to form crystals, and isolating the crystals by known methods, such as filtration. Analytical techniques such as infrared spectroscopy can be used to confirm the presence of solvent in the solvate crystals.

[0135] In some aspects of the disclosure, the USP1 inhibitor and / or chemotherapeutic agent is deuterated. In some aspects, the USP1 inhibitor and / or chemotherapeutic agent is partially or fully deuterated, ie, one or more hydrogen atoms are replaced with a deuterium atom.

[0136] The term "amorphous" as applied to chemical compounds refers to a state in which the material lacks long-range order at the molecular level and can exhibit the physical properties of either a solid or a liquid, depending on the temperature. Typically, such materials do not produce a distinct X-ray diffraction pattern and, although they have the characteristics of a solid, are more formally described as liquids. When heated, the solid properties are converted to liquid properties, characterized by a change of state, usually a second-order transition (the "glass transition").

[0137] The term "polymorph" as used herein refers to a crystalline form of a compound or its salt, hydrate or solvate in a specific crystal packing arrangement. All polymorphs have the same elemental composition. The term "crystalline" as used herein refers to a solid state form consisting of orderly arranged structural units. Different crystalline forms of the same compound or its salts, co-crystals, hydrates or solvates are caused by different packing of molecules in the solid state, which leads to different crystal symmetry and / or unit cell parameters. Different crystal forms usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability and solubility. For example, see Remington's Pharmaceutical Sciences, 18 th ed., Mack Publishing, Easton PA, 173 (1990); The United States Pharmacopeia, 23r d ed., 1843-1844 (1995) (incorporated herein by reference).

[0138] Crystalline forms are most commonly characterized by X-ray powder diffraction (XRPD). The reflectance pattern (peaks, usually expressed in 2θ degrees) of the XRPD is generally considered to be the fingerprint of a particular crystalline form. The relative intensities of the XRPD peaks vary greatly depending on factors such as sample preparation techniques, crystal size distribution, filters, sample installation procedures, and the specific instrument used. In some aspects, new peaks may be observed or existing peaks may disappear, depending on the type or setting of the instrument. In some aspects, any particular peak in the XRPD spectrum may appear as a single peak, a double peak, a triple peak, a quadruple peak, or multiple peaks, depending on the type or setting of the instrument, the sensitivity of the instrument, the measurement conditions, and / or the purity of the crystalline form. In some aspects, any particular peak in the XRPD may be symmetrical or asymmetrical, such as having a shoulder. Those skilled in the art who understand these variations can use XRPD and other known physicochemical techniques to identify or determine the defining features or characteristics of a particular crystalline form.

[0139] In various aspects, a USP1 inhibitor reduces the level of USP1 protein and / or inhibits or reduces at least one biological activity of USP1 protein.

[0140] In some aspects, the USP1 inhibitor specifically binds to the USP1 protein. In some aspects, the USP1 inhibitor specifically binds to the USP1 protein in the USP1-UAF1 complex. In some aspects, the USP1 inhibitor specifically binds to the USP1 mRNA. In some aspects, the USP1 inhibitor specifically binds to the USP1 protein (alone or in the USP1-UAF1 complex) or the USP1 mRNA. In some aspects, the USP1 inhibitor specifically binds to UAF1 (alone or in the USP1-UAF1 complex) and inhibits or reduces the formation or activity of the USP1-UAF1 complex.

[0141] In some aspects, USP1 inhibitors reduce the formation of USP1-UAF1 complexes. In some aspects, USP1 inhibitors reduce the activity of USP1-UAF1 complexes. In some aspects, USP1 inhibitors reduce the deubiquitinase activity of USP1. In some aspects, USP1 inhibitors increase monoubiquitinated PCNA. In some aspects, USP1 inhibitors increase monoubiquitinated FANCD2. In some aspects, USP1 inhibitors increase monoubiquitinated FANCI.

[0142] In some aspects, the USP1 inhibitor does not bind to other deubiquitinating enzymes, other USP proteins, or other UAF1 complexes (e.g., USP46-UAF1), or binds with an affinity that is 5-fold, at least 10-fold, at least 20-fold, or at least 100-fold less than the affinity for USP1 (i.e., the K of the USP1 inhibitor for other deubiquitinating enzymes, other USP proteins, or other UAF1 complexes (e.g., USP46-UAF1) is less than 100-fold). D Comparison of K of USP1 D at least 5-fold, at least 10-fold, at least 20-fold, or at least 100-fold greater) in binding to deubiquitinating enzymes, other USP proteins, or other UAF1 complexes (e.g., USP46-UAF1).

[0143] In some aspects, the USP1 inhibitor inhibits USP1 deubiquitinase activity with an IC50 of less than about 50 nM, between about 50 nM and about 200 nM, between about 200 nM and about 2 pM, or more than 2 pM, for example, as measured using an assay disclosed in U.S. Patent Application Publication No. 2017 / 0145012, or an IC50 of 50 nM to 1000 nM, for example, as measured using an assay disclosed in Liang et al., Nat Chem Biol 10: 289-304 (2014). In some aspects, the USP1 inhibitor inhibits USP1 deubiquitinase activity with an IC50 as measured using an assay disclosed in Chen, et al., Chem Biol., 18(11): 1390-1400 (2011). In some aspects, the USP1 inhibitor does not inhibit the activity of other deubiquitinases, other USP proteins, or other UAF1 complexes (e.g., USP46-UAF1), or inhibits the activity of other deubiquitinases, other USP proteins, or other UAF1 complexes (e.g., USP46-UAF1) with an IC50 that is at least 5-fold, at least 10-fold, at least 20-fold, or at least 100-fold higher than the IC50 for inhibiting USP1 deubiquitinase activity.

[0144] In some aspects, the USP1 inhibitors of the present disclosure bind to the USP1 protein with an affinity in the range of 1 pM to 100 μM, or 1 pM to 1 μM, or 1 pM to 500 nM, or 1 pM to 100 nM. In some aspects, the USP1 inhibitors of the present disclosure bind to the USP1 protein with an affinity of about 1 pM to about 100 μM, about 1 nM to about 100 μM, about 1 μM to about 1001 μM, about 1 μM to about 50 μM, about 1 μM to about 40 μM, about 1 μM to about 30 μM, about 1 μM to about 20 μM, or about 1 μM to about 101 μM, about 1 μM, about 5 μM, about 10 μM, about 15 μM, about 20 μM, about 25 μM, about 30 μM, about 35 μM, about 40 μM, about 45 μM, about 50 μM, about 60 μM, about 70 μM, about 80 μM, about 90 μM, or about 100 μM. In some aspects, the USP1 inhibitors of the present disclosure are present in an amount of about 100 nM to about 1 μM, about 100 nM to about 900 nM, about 100 nM to about 800 nM, about 100 nM to about 700 nM, about 100 nM to about 600 nM, about 100 nM to about 500 nM, about 100 nM to about 400 nM, about 100 nM to about 300 nM, about 100 nM to about 200 nM, about 200 nM to about 1 μM, about 300 nM to about 400 nM, about 100 nM to about 500 nM, about 100 nM to about 600 nM, about 100 nM to about 700 nM, about 100 nM to about 800 nM, about 100 nM to about 900 nM, about 100 nM to about 1000 nM The USP1 protein is bound to the USP1 protein with an affinity of 0 nM to about 1 μM, about 400 nM to about 1 μM, about 500 nM to about 1 μM, about 600 nM to about 1 μM, about 700 nM to about 1 μM, about 800 nM to about 1 μM, about 900 nM to about 1 μM, about 100 nM, about 200 nM, about 300 nM, about 400 nM, about 500 nM, about 600 nM, about 700 nM, about 800 nM or about 900 nM. In some aspects, the USP1 inhibitors of the present disclosure are present in an amount of about 1 nM to about 100 nM, 1 nM to about 90 nM, 1 nM to about 80 nM, 1 nM to about 70 nM, 1 nM to about 60 nM, 1 nM to about 50 nM, 1 nM to about 40 nM, 1 nM to about 30 nM, 1 nM to about 20 nM, 1 nM to about 10 nM, about 10 nM to about 100 nM, about 20 nM to about 100 nM, about 30 nM to about 100 nM, about 40 nM to about 100 nM, about 50 nM to about 100 nM, The USP1 protein is bound with an affinity of about 100 nM, about 60 nM to about 100 nM, about 70 nM to about 100 nM, about 80 nM to about 100 nM, about 90 nM to about 100 nM, about 1 nM, about 2 nM, about 3 nM, about 4 nM, about 5 nM, about 6 nM, about 7 nM, about 8 nM, about 9 nM, about 10 nM, about 20 nM, about 30 nM, about 40 nM, about 50 nM, about 60 nM, about 70 nM, about 80 nM, about 90 nM or about 100 nM.

[0145] In some aspects, the USP1 inhibitors of the present disclosure bind to USP1 protein with an affinity of less than 1 μM, less than 500 nM, less than 100 nM, less than 10 nM, or less than 1 nM. In some aspects, the USP1 inhibitors bind to USP1 protein with an affinity of less than 1 nM.

[0146] In some aspects, the USP1 inhibitors of the present disclosure have an IC of 1 pM to 100 μM, or 1 pM to 1 μM, or 1 pM to 500 nM, or 1 pM to 100 nM. 50 Inhibition of USP1 activity. In some aspects, the USP1 inhibitor has an IC of about 1 pM to about 100 μM, about 1 nM to about 100 μM, about 1 μM to about 100 μM, about 1 μM to about 50 μM, about 1 μM to about 40 μM, about 1 μM to about 30 μM, about 1 μM to about 20 μM, or about 1 μM to about 10 μM, about 1 μM, about 5 μM, about 10 μM, about 15 μM, about 20 μM, about 25 μM, about 30 μM, about 35 μM, about 40 μM, about 45 μM, about 50 μM, about 60 μM, about 70 μM, about 80 μM, about 90 μM, or about 100 μM. 50 Inhibit USP1 activity. In some aspects, the USP1 inhibitor is present at about 100 nM to about 1 μM, about 100 nM to about 900 nM, about 100 nM to about 800 nM, about 100 nM to about 700 nM, about 100 nM to about 600 nM, about 100 nM to about 500 nM, about 100 nM to about 400 nM, about 100 nM to about 300 nM, about 100 nM to about 200 nM, about 200 nM to about 1 μM. , about 300 nM to about 1 μM, about 400 nM to about 1 μM, about 500 nM to about 1 μM, about 600 nM to about 1 μM, about 700 nM to about 1 μM, about 800 nM to about 1 μM, about 900 nM to about 1 μM, about 100 nM, about 200 nM, about 300 nM, about 400 nM, about 500 nM, about 600 nM, about 700 nM, about 800 nM, or about 900 nM. 50 Inhibits USP1 activity.

[0147] In some aspects, the USP1 inhibitors of the present disclosure are present in an amount of about 1 nM to about 100 nM, 1 nM to about 90 nM, 1 nM to about 80 nM, 1 nM to about 70 nM, 1 nM to about 60 nM, 1 nM to about 50 nM, 1 nM to about 40 nM, 1 nM to about 30 nM, 1 nM to about 20 nM, 1 nM to about 10 nM, about 10 nM to about 100 nM, about 20 nM to about 100 nM, about 30 nM to about 100 nM, about 40 nM to about 100 nM, An IC of about 50 nM to about 100 nM, about 60 nM to about 100 nM, about 70 nM to about 100 nM, about 80 nM to about 100 nM, about 90 nM to about 100 nM, about 1 nM, about 2 nM, about 3 nM, about 4 nM, about 5 nM, about 6 nM, about 7 nM, about 8 nM, about 9 nM, about 10 nM, about 20 nM, about 30 nM, about 40 nM, about 50 nM, about 60 nM, about 70 nM, about 80 nM, about 90 nM, or about 100 nM 50 Inhibit USP1 activity. In some aspects, the USP1 inhibitor has an IC of less than 1 μM, less than 500 nM, less than 100 nM, less than 10 nM, or less than 1 nM. 50 Inhibit USP1 activity. In some aspects, the USP1 inhibitor has an IC of less than 1 nM. 50 Inhibits USP1 activity. Exemplary assay for USP1 inhibition

[0148] Any suitable assay in the art can be used to determine activity, detect results or effects, or determine efficacy. For example, suitable assays are provided in U.S. Publication No. US20210115049A1.

[0149] In some cases, methods for determining whether a USP1 inhibitor compound inhibits USP1 deubiquitinase activity measure a change in mass after cleavage of diubiquitin occurs upon binding of a deubiquitinase. For example, ubiquitin aldehyde and ubiquitin vinyl sulfone form a covalent, irreversible bond with a deubiquitinase, which results in an observable mass change of the deubiquitinase. Similarly, cleavage of diubiquitin results in an observable mass change.

[0150] In some cases, methods for determining whether a USP1 inhibitor compound inhibits USP1 deubiquitinase activity involve an increase in luminescence or fluorescence after cleavage, which can be monitored, for example, on a disc reader. Such assays can use ubiquitin linked to a fluorophore via a linker, such as ubiquitin-7-amino-4-methylcoumarin (Ub-AMC) or ubiquitin-rhodamine 110. Such assays can also use diubiquitin containing an isopeptide bond. An exemplary diubiquitin can include a fluorophore on one ubiquitin and a quencher on another ubiquitin, such that fluorescence increases following ubiquitin cleavage. Such assays can also use an enzyme-coupled system in which ubiquitin is coupled to an enzyme that is effective in producing a fluorescent enzyme product only when released from the ubiquitin. II. Chemotherapeutic Agents

[0151] In some aspects, the chemotherapeutic agent of the present disclosure is a platinum, a monofunctional alkylating agent, a difunctional alkylating agent, an antimetabolite, a topoisomerase inhibitor, or a combination thereof.

[0152] In some aspects, the chemotherapeutic agent is platinum.

[0153] In some aspects, the platinum is selected from the group consisting of cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, nedaplatin, and triplatin.

[0154] In some aspects, the chemotherapeutic agent is cisplatin or carboplatin.

[0155] In some aspects, the chemotherapeutic agent is a monofunctional alkylating agent. In some aspects, the monofunctional alkylating agent is selected from the group consisting of alkyl sulfonates, nitrosoureas, and temozolomide.

[0156] In some aspects, the chemotherapeutic agent is a bifunctional alkylating agent. In some aspects, the bifunctional alkylating agent is selected from the group consisting of nitrogen mustard and mitomycin C.

[0157] In some aspects, the chemotherapeutic agent is an antimetabolite. In some aspects, the antimetabolite is selected from the group consisting of gemcitabine, 5-fluorouracil, thiopurines, and folic acid analogs.

[0158] In some aspects, the chemotherapeutic agent is a topoisomerase inhibitor. In some aspects, the topoisomerase inhibitor is selected from the group consisting of camptothecin, anthracycline and etoposide.

[0159] In various aspects, the platinum of the present disclosure is a platinum-containing compound. Platinum-containing compounds include agents such as cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, nedaplatin and triplatin. Platinum-containing compounds cause DNA to crosslink in the form of monoadducts, interchain crosslinks, intrachain crosslinks or DNA protein crosslinks. The resulting crosslinks inhibit DNA repair and / or DNA synthesis in cancer cells. These compounds are sometimes described as alkylating-like agents, although they do not have alkyl groups. Cisplatin was the first platinum-containing compound discovered and was first approved by the U.S. Food and Drug Administration in 1978. Carboplatin was introduced in the 1980s and has been shown to have lower side effects than cisplatin in ovarian and lung cancer (Hartmann and Lipp, Exper. Opin. Pharmacother. 2003, 4 (6) 889-901).

[0160] In some aspects, platinum is cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, nedaplatin or triplatin. In some aspects, platinum is nedaplatin, cisplatin, carboplatin or oxaliplatin. In some aspects, platinum is cisplatin, carboplatin or oxaliplatin. In some aspects, platinum is cisplatin or carboplatin. In some aspects, platinum is cisplatin. In some aspects, platinum is carboplatin.

[0161] In various aspects, the alkylating agent of the present disclosure is an alkylating agent for cancer treatment, which connects an alkyl group to DNA. Since cancer cells usually proliferate faster and have fewer errors than healthy cells, cancer cells are more sensitive to DNA damage (e.g., alkylation). In some aspects, the alkylating agent is active under conditions present in the cell. In some aspects, the alkylating agent directly attacks DNA by cross-linking the guanine nucleobases in the DNA double helix, thereby preventing tumor growth. In some aspects, the alkylating agent can be a monofunctional alkylating agent or a difunctional alkylating agent. In some aspects, the monofunctional alkylating agent can only react with one guanine residue of DNA. In some aspects, the difunctional alkylating agent can react with two different guanine residues of DNA.

[0162] In some aspects, the monofunctional alkylating agent is an alkyl sulfonate, a nitrosourea, or temozolomide. In some aspects, the monofunctional alkylating agent is an alkyl sulfonate. In some aspects, the monofunctional alkylating agent is a nitrosourea. In some aspects, the monofunctional alkylating agent is temozolomide. In some aspects, the bifunctional alkylating agent is a nitrogen mustard or mitomycin C. In some aspects, the bifunctional alkylating agent is a nitrogen mustard. In some aspects, the bifunctional alkylating agent is mitomycin C.

[0163] In various aspects, the antimetabolite of the present disclosure is a chemical substance that inhibits the use of metabolites. In some aspects, the structure of antimetabolites is similar to the metabolites that they interfere with usually. Therefore, competitive inhibition can occur, and the presence of antimetabolites can produce toxic effects on cells, such as stopping cell growth and cell division. In some aspects, antimetabolites are used for cancer treatment. In some aspects, antimetabolites interfere with DNA production, therefore interfering with cell division and tumor growth. In some aspects, antimetabolites damage DNA replication by incorporating chemically altered nucleotides or by consuming the deoxynucleotides required for DNA replication and cell proliferation.

[0164] In some aspects, antimetabolites are gemcitabine, 5-fluorouracil, thiopurine, folic acid analogs, capecitabine, cytarabine, floxuridine, fludarabine or hydroxyurea. In some aspects, antimetabolites are gemcitabine, 5-fluorouracil, thiopurine or folic acid analogs. In some aspects, antimetabolites are gemcitabine. In some aspects, antimetabolites are 5-fluorouracil. In some aspects, antimetabolites are thiopurine. In some aspects, antimetabolites are folic acid analogs, including methotrexate, pemetrexed, mitrexed, proguanil, pyrimethamine, trimethoprim and folinate.

[0165] In various aspects, the topoisomerase inhibitors of the present disclosure are compounds that block the action of topoisomerase. Topoisomerase plays an important role in cell reproduction and DNA organization. Topoisomerase mediates the cleavage of single-stranded and double-stranded DNA to relax supercoils, unwind catenoids and condense chromosomes in eukaryotic cells. In some aspects, topoisomerase inhibitors prevent topoisomerase from performing DNA chain breaks. In some aspects, topoisomerase inhibitors associate with topoisomerase-DNA complexes and prevent the reconnection step of the topoisomerase mechanism. These topoisomerase-DNA inhibitor complexes are cytotoxic agents because the unrepaired single-stranded and double-stranded DNA breaks they cause can lead to apoptosis and cell death. In some aspects, topoisomerase inhibitors are used as therapeutic agents for infectious and cancerous cells.

[0166] In some aspects, the topoisomerase inhibitor is camptothecin, topotecan, irinotecan, belotecan, indenoisoquinoline, phenanthridine, indolecarbazole, anthracycline, etoposide, teniposide, dapoxetine, novobiocin or mebarone. In some aspects, the topoisomerase inhibitor is camptothecin, anthracycline or etoposide. In some aspects, the topoisomerase inhibitor is camptothecin. In some aspects, the topoisomerase inhibitor is anthracycline. In some aspects, the topoisomerase inhibitor is etoposide.

[0167] In some aspects, the chemotherapeutic agent can be a DNA damaging agent. III. Treatment Methods

[0168] Since the compositions of the present disclosure are (i) chemotherapeutic agents and (ii) ubiquitin-specific processing protease 1 (USP1) inhibitors having Formula I, the present disclosure provides a method of damaging DNA and / or inhibiting USP1 protein comprising administering one or more compositions of the present disclosure.

[0169] Since the compositions of the present disclosure are (i) chemotherapeutic agents and (ii) ubiquitin-specific processing protease 1 (USP1) inhibitors having Formula I, the present disclosure generally relates to a method for treating a disease, condition, or disorder responsive to DNA damage and / or USP1 protein inhibition in a subject suffering from or at risk of suffering from the disease, the method comprising administering to the subject an effective amount of one or more compositions of the present disclosure.

[0170] The present disclosure also relates to a method of damaging DNA and / or inhibiting USP1 protein in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition of the present disclosure.

[0171] In some aspects, the compositions of the present disclosure can be used to damage DNA and / or inhibit the activity of USP1 protein. For example, in some aspects, the method of damaging DNA and / or inhibiting USP1 protein comprises contacting DNA and / or USP1 protein with the compositions of the present disclosure. The contacting can occur in vitro or in vivo.

[0172] In some aspects, the compositions of the present disclosure can be used to treat diseases mediated by DNA and / or USP1 proteins. Diseases mediated by DNA and / or USP1 proteins are any pathological conditions in which DNA and / or USP1 proteins are known to play a role. In some aspects, diseases mediated by DNA and / or USP1 proteins are proliferative diseases, such as cancer. In some aspects, the compositions of the present disclosure can delay, reduce or prevent rebound (rapid regrowth) of tumors. In some aspects, the toxicity of the compositions of the present disclosure is not significantly higher than that of a single chemotherapeutic agent. In some aspects, the toxicity of the compositions of the present disclosure is not significantly higher than that of a single USP1 inhibitor. In some aspects, the toxicity of the compositions of the present disclosure is not significantly higher than that of a single chemotherapeutic agent or a single USP1 inhibitor.

[0173] In some aspects, the compositions of the disclosure are less toxic than the chemotherapeutic agent alone. In some aspects, the compositions of the disclosure are less toxic than the USP1 inhibitor alone. In some aspects, the compositions of the disclosure are less toxic than the chemotherapeutic agent alone or the USP1 inhibitor alone.

[0174] In some aspects, the compositions of the present disclosure are administered in an effective amount to reduce unacceptable toxicity and / or unacceptable adverse reactions of chemotherapeutic agents administered as monotherapy. In some aspects, the compositions of the present disclosure are administered in an effective amount to reduce unacceptable toxicity and / or unacceptable adverse reactions of USP1 inhibitors administered as monotherapy. In some aspects, the compositions of the present disclosure are administered in an effective amount to reduce unacceptable toxicity and / or unacceptable adverse reactions of chemotherapeutic agents administered as monotherapy or USP1 inhibitors administered as monotherapy. Exemplary toxicities or adverse reactions include hematological toxicities, such as thrombocytopenia, anemia or neutropenia, pneumonia, dyspnea, fever, cough, wheezing, radiological abnormalities, hypertension, myelodysplastic syndrome / acute myeloid leukemia (MDS / AML), nausea and / or fatigue.

[0175] Provided herein are various methods of treating diseases and disorders with the combinations of the present disclosure. Exemplary diseases and disorders that can be treated with the compositions of the present disclosure include, but are not limited to, cancer.

[0176] In some aspects, methods of treating cancer with a combination of the present disclosure are provided. Such methods include administering a therapeutically effective amount of a composition of the present disclosure to a subject suffering from cancer.

[0177] In some aspects, such methods comprise (a) identifying a cancer in a subject as a chemotherapeutic agent and / or USP1 inhibitor sensitive cancer, and then (b) administering to the subject a therapeutically effective amount of a composition of the disclosure.

[0178] In some aspects, the subject's cancer cells are homologous recombination repair (HRR) positive.

[0179] In some aspects, the cancer to be treated with the compositions of the present disclosure is an advanced solid tumor. Advanced solid tumors are solid tumors that are unresectable and / or metastatic. In other aspects, the cancer to be treated with the compositions of the present disclosure is a resectable solid tumor, whether benign or metastatic, wherein the composition is administered before and / or after resection surgery.

[0180] In some aspects, the cancer to be treated with the composition of the present disclosure is selected from lung cancer, non-small cell lung cancer (NSCLC), colon cancer, bladder cancer, osteosarcoma, ovarian cancer, skin cancer, uterine cancer, peritoneal cancer, endometrial cancer, pancreatic cancer, gastric cancer, bile duct cancer, and breast cancer. In some aspects, the cancer is lung cancer. In some aspects, the cancer is non-small cell lung cancer (NSCLC). In some aspects, the cancer is colon cancer. In some aspects, the cancer is bladder cancer. In some aspects, the cancer is osteosarcoma. In some aspects, the cancer is ovarian cancer. In some aspects, the cancer is skin cancer. In some aspects, the cancer is uterine cancer. In some aspects, the cancer is peritoneal cancer. In some aspects, the cancer is endometrial cancer. In some aspects, the cancer is breast cancer.

[0181] In some aspects, the cancer to be treated with the composition of the present disclosure has been previously treated with a platinum therapy. In some aspects, the cancer to be treated with the composition of the present disclosure is a platinum-resistant cancer. In some aspects, the cancer to be treated with the composition of the present disclosure is a platinum-refractory cancer. In some aspects, the platinum therapy is selected from the group consisting of cisplatin, carboplatin, oxaliplatin, and combinations thereof.

[0182] In some aspects, the chemotherapeutic agent and the USP1 inhibitor are administered sequentially. In some aspects, the chemotherapeutic agent is administered first, followed by the USP1 inhibitor. In some aspects, the USP1 inhibitor is administered first, followed by the chemotherapeutic agent. In some aspects, the chemotherapeutic agent and the USP1 inhibitor are administered simultaneously.

[0183] In some aspects, the compositions of the present disclosure are administered in a therapeutically effective amount sufficient to produce one or more therapeutic effects selected from the group consisting of: (i) reducing tumor size, (ii) increasing tumor regression rate, and (iii) reducing or inhibiting tumor growth. In some aspects, the compositions of the present disclosure are administered in a therapeutically effective amount sufficient to produce the effect of reducing tumor size. In some aspects, the compositions of the present disclosure are administered in a therapeutically effective amount sufficient to produce the effect of increasing tumor regression rate. In some aspects, the compositions of the present disclosure are administered in a therapeutically effective amount sufficient to produce the effect of reducing or inhibiting tumor growth.

[0184] In some embodiments, the chemotherapeutic agent is administered at an approved dose for a specific indication. In other embodiments, the chemotherapeutic agent is administered at any dose disclosed herein. In some embodiments, the platinum-based chemotherapeutic is cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, nedaplatin, triplatin, levitra or a combination thereof. In certain embodiments, the platinum-based chemotherapy is any other platinum-based chemotherapy known in the art. In some embodiments, the chemotherapeutic agent is the nucleotide analog gemcitabine. In one embodiment, the chemotherapeutic agent is a folic acid antimetabolite. In one embodiment, the folic acid antimetabolite is pemetrexed.

[0185] In some aspects, a USP1 inhibitor, gemcitabine, and carboplatin are administered to a subject. In some aspects, the subject suffers from ovarian cancer, triple-negative breast cancer, or non-small cell lung cancer. In some aspects, the subject suffers from ovarian cancer. In some aspects, the subject suffers from triple-negative breast cancer. In some aspects, the subject suffers from non-small cell lung cancer.

[0186] In some aspects, a USP1 inhibitor, folinic acid, 5-fluorouracil, and oxaliplatin are administered to a subject. In some aspects, the subject has colorectal cancer, pancreatic cancer, bile duct cancer, esophageal cancer, or gastric cancer. In some aspects, the subject has colorectal cancer. In some aspects, the subject has pancreatic cancer. In some aspects, the subject has bile duct cancer. In some aspects, the subject has esophageal cancer. In some aspects, the subject has gastric cancer.

[0187] In some aspects, the USP1 inhibitor and the chemotherapeutic agent are provided in the same dosage form. In some aspects, the USP1 inhibitor is provided in an oral dosage form. In some aspects, the chemotherapeutic agent is provided in an oral dosage form. In some aspects, the USP1 inhibitor and the chemotherapeutic agent are provided in separate dosage forms. In some aspects, the USP1 inhibitor is provided in an oral dosage form. In some aspects, the chemotherapeutic agent is provided in an injectable dosage form.

[0188] In some aspects, the subject is a mammal. In some aspects, the mammal is a human.

[0189] In some aspects, the compositions of the disclosure are used in combination with one or more additional therapeutic agents for treating cancer.

[0190] In some aspects, provided herein are combinations of the disclosure for use as a medicament or for the preparation of a medicament, for example, for the treatment of cancer. In some aspects, provided herein are combinations of the disclosure for use in a method of treating cancer. IV. Pharmaceutical Compositions and Kits

[0191] The combination of the present disclosure can be administered to a mammal in the form of a raw chemical substance without any other components, or the combination of the present disclosure can also be administered to a mammal as part of a pharmaceutical composition containing a compound in combination with a suitable pharmaceutically acceptable carrier (see, e.g., Gennaro, Remington: The Science and Practice of Pharmacy with Facts and Comparisons: Drugfacts Plus, 20th ed. (2003); Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed., Lippencott Williams and Wilkins (2004); Kibbe et al., Handbook of Pharmaceutical Excipients, 3rd ed., Pharmaceutical Press (2000)). Such carriers can be selected from pharmaceutically acceptable excipients and adjuvants. The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable vehicle" encompasses any of the standard pharmaceutical carriers, solvents, surfactants or vehicles. Standard pharmaceutical carriers and their formulation are described in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 19th ed. 1995. The USP1 inhibitor and chemotherapeutic agent may be present in the same pharmaceutical composition; or the USP1 inhibitor and chemotherapeutic agent may be present in separate pharmaceutical compositions that may be administered simultaneously or sequentially.

[0192] The pharmaceutical combination compositions of the present disclosure can be prepared as liquid suspensions or solutions using liquids such as oils, water, alcohols, and combinations of these substances.

[0193] As provided herein, USP1 inhibitors (e.g., 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine or a pharmaceutically acceptable salt, solvate, hydrate or co-crystal thereof) can be present in any pharmaceutical composition including all compositions in which such inhibitors are combined with one or more pharmaceutically acceptable carriers. In some aspects, the USP1 inhibitor is present in the composition in an amount effective to achieve its intended therapeutic purpose.

[0194] In some aspects, the present disclosure provides a pharmaceutical composition comprising a USP1 inhibitor (e.g., 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine or a pharmaceutically acceptable salt, solvate, hydrate or co-crystal thereof) and a pharmaceutically acceptable carrier. In some aspects, the pharmaceutical composition comprises crystalline Form 2 of gentisic acid co-crystal of Compound 1.

[0195] Pharmaceutical combination compositions within the scope of the present disclosure include all compositions in which the USP1 inhibitor of the present disclosure and the chemotherapeutic agent are combined with one or more pharmaceutically acceptable carriers. In one aspect, the USP1 inhibitor of the present disclosure and the chemotherapeutic agent are present in the composition in amounts effective to achieve their intended therapeutic purpose.

[0196] The pharmaceutical compositions of the present disclosure can be orally administered in any orally acceptable dosage form, including capsules, tablets, aqueous suspensions or solutions. In some aspects, the capsule is a gelatin capsule.

[0197] When administered orally, known carriers may be added to the pharmaceutical composition. For example, microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be used in tablets together with various disintegrants such as starch (preferably corn, potato or tapioca starch), methylcellulose, alginic acid and certain complex silicates, and granulation binders such as polyvinyl pyrrolidone, sucrose, gelatin and acacia. In addition, lubricants such as magnesium stearate, sodium lauryl sulfate and talc are also commonly used in tablets. Similar types of solid ingredients may also be used as fillers for gelatin capsules. Preferred materials in this regard include lactose or milk sugar and high molecular weight polyethylene glycols. When oral aqueous suspensions and / or elixirs are required, the active ingredient may be combined with various sweeteners or flavorings, colorants or dyes, emulsifiers and / or suspending agents (if necessary) and diluents such as water, ethanol, propylene glycol, glycerol and various similar compositions.

[0198] Pharmaceutical compositions for in vivo administration may be sterile. This can be achieved by filtering through a sterile filtration membrane or the like.

[0199] Pharmaceutical compositions within the scope of the present disclosure include all compositions in which a USP1 inhibitor is combined with one or more pharmaceutically acceptable carriers. In some aspects, the USP1 inhibitor is present in the composition in an amount effective to achieve its intended therapeutic purpose.

[0200] The pharmaceutical compositions of the present disclosure may be administered to any patient who may experience the beneficial effects of the compounds of the present disclosure. The most important of these patients are mammals, such as humans and pets, although the present disclosure is not intended to be so limited. In some aspects, the patient is a human. In some aspects, the pharmaceutical compositions of the present disclosure may be administered to patients with chemotherapeutic-resistant or refractory cancers. In some aspects, the pharmaceutical compositions of the present disclosure may be administered to patients with chemotherapeutic-resistant or refractory BRCA1-deficient cancers. In some aspects, the pharmaceutical compositions of the present disclosure may be administered to patients with platinum-resistant or platinum-refractory cancers.

[0201] In some aspects, the present disclosure provides a kit comprising a USP1 inhibitor (e.g., 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine or a pharmaceutically acceptable salt, solvate, hydrate or co-crystal thereof) or a pharmaceutical composition comprising the same, packaged in a manner that facilitates its use in practicing the methods of the present disclosure. In some aspects, the kit comprises a USP1 inhibitor packaged in a container (e.g., a sealed bottle or container), the container having a label affixed thereto or contained in the kit, the label indicating that the USP1 inhibitor or its pharmaceutical composition is used to practice the methods of the present disclosure. In some aspects, the USP1 inhibitor is packaged in unit dosage form. The kit may also include a device suitable for administering the USP1 inhibitor or its pharmaceutical composition according to a predetermined route of administration. In some aspects, the present disclosure provides a kit comprising a USP1 inhibitor or its pharmaceutical composition, and instructions for administering the inhibitor or composition to a cancer patient.

[0202] In some aspects, the present disclosure provides a pharmaceutical composition comprising a USP1 inhibitor (e.g., 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine or a pharmaceutically acceptable salt, solvate, hydrate or cocrystal thereof) and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is used to treat cancer (e.g., a solid tumor). In some aspects, the cancer is an advanced solid tumor.

[0203] In some aspects, the present disclosure provides a pharmaceutical composition comprising a USP1 inhibitor (e.g., 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine or a pharmaceutically acceptable salt, solvate, hydrate or cocrystal thereof) and a chemotherapeutic agent and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is used to manufacture a medicament for treating cancer (e.g., solid tumors). V. Preparation method of USP1 inhibitor

[0204] USP1 inhibitors for the uses and methods provided herein can be prepared in any manner. For example, methods for synthesizing USP1 inhibitors are provided in WO2020 / 132269 and WO2022 / 094096, the entirety of each of which is incorporated herein by reference.

[0205] In some aspects, the USP1 inhibitor is prepared by the following method: a) adding an appropriate amount of compound 1 to an appropriate amount of a suitable solvent system to obtain a suspension; b) stirring the suspension; and c) collecting the solid product from step b). In some aspects, a suitable pharmaceutically acceptable acid is added in step a). In some aspects, the suitable solvent system is selected from acetonitrile, acetone, cyclohexane, dichloromethane, dimethylacetamide, dimethyl sulfoxide, ethanol, ethyl acetate, ethanol isopropyl ester, isopropyl acetate, methanol methyl ethyl ketone, 4-methyl-2-pentanone, methyl tert-butyl ether, 2-methyltetrahydrofuran, n-heptane, n-methylpyrrolidone, tetrahydrofuran, toluene, water and mixtures thereof. In some aspects, the suitable solvent system is selected from the group consisting of ethyl acetate, n-heptane and mixtures thereof.

[0206] In some aspects, the preparation method of the USP1 inhibitor comprises a) dissolving an appropriate amount of compound 1 in an appropriate amount of solvent to form a solvate; b) adding an appropriate amount of anti-solvent; c) adding seed crystals of the solid form of compound 1; d) stirring the resulting suspension; and e) collecting the solid product generated in step d). In some aspects, the method further comprises adding a suitable pharmaceutically acceptable acid in step a). In some aspects, the method further comprises adding a suitable anti-solvent after step c) and before step d). In some aspects, suitable solvents and anti-solvents are selected from the group consisting of acetonitrile, acetone, cyclohexane, dichloromethane, dimethylacetamide, dimethyl sulfoxide, ethanol, ethyl acetate, ethanol isopropyl ester, isopropyl acetate, methanol methyl ethyl ketone, 4-methyl-2-pentanone, methyl tert-butyl ether, 2-methyltetrahydrofuran, n-heptane, n-methylpyrrolidone, tetrahydrofuran, toluene, water and mixtures thereof. In some aspects, suitable solvents and anti-solvents are selected from the group consisting of ethyl acetate, n-heptane and mixtures thereof. In some aspects, the suitable solvent is ethyl acetate. In some aspects, a suitable anti-solvent is n-heptane.

[0207] In some aspects, Compound 1 is added to a suitable solvent system at a temperature of about room temperature to about 100° C., or about room temperature to about 75° C., or about room temperature to about 50° C., or about room temperature to about 40° C. In some aspects, Compound 1 is added to a suitable solvent system at about room temperature.

[0208] In some aspects, the USP1 inhibitor is a crystalline form 2 of the gentisic acid cocrystal of Compound 1, prepared by a method comprising: a) adding an appropriate amount of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and gentisic acid to an appropriate amount of a suitable solvent system at room temperature to obtain a suspension; b) stirring the suspension from step a); and c) collecting the solid product from step b). In some aspects, the suitable solvent system is selected from the group consisting of ethyl acetate, n-heptane, and mixtures thereof.

[0209] In some aspects, the USP1 inhibitor is a crystalline Form 2 of gentisic acid cocrystal of Compound 1, and its preparation method comprises a) dissolving an appropriate amount of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and gentisic acid in an appropriate amount of a suitable solvent to prepare a solvate at room temperature; b) adding an appropriate amount of a suitable anti-solvent; c) adding seed crystals of crystalline Form 2 of gentisic acid cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Compound 1; d) stirring the obtained suspension; and e) collecting the solid product generated in step d). In some aspects, the method further comprises adding a suitable anti-solvent after step c) and before step d). In some aspects, the suitable solvent is ethyl acetate. In some aspects, the suitable anti-solvent is n-heptane.

[0210] In some aspects, the USP1 inhibitor is crystalline Form 2 of the gentisic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Compound 1 prepared by any of the methods disclosed herein. Example Example 1: Maximum tolerated dose of compound 1 cocrystal combined with cisplatin in non-tumor bearing Balb / c nude mice

[0211] The maximum tolerated dose (MTD) of the USP1 inhibitor compound 1 cocrystal combined with cisplatin was evaluated in non-tumor-bearing Balb / c nude mice. Female Balb / c nude mice aged 6-8 weeks from Beijing Anikepu Biotechnology Co., Ltd. were randomly divided into 5 groups, namely, control group, cisplatin (4 mg / kg) alone group, cisplatin (5 mg / kg) alone group, cisplatin (6 mg / kg) alone group, compound 1 (50 mg / kg) and cisplatin (4 mg / kg) combination group, compound 1 (100 mg / kg) and cisplatin (4 mg / kg) combination group, and compound 1 (300 mg / kg) and cisplatin (4 mg / kg) combination group , compound 1 (50 mg / kg) and cisplatin (5 mg / kg) combination group, compound 1 (100 mg / kg) and cisplatin (5 mg / kg) combination group, compound 1 (300 mg / kg) and cisplatin (5 mg / kg) combination group, compound 1 (50 mg / kg) and cisplatin (6 mg / kg) combination group, compound 1 (100 mg / kg) and cisplatin (6 mg / kg) combination group, compound 1 (300 mg / kg) and cisplatin (6 mg / kg) combination group. Mice were administered the corresponding dose of compound 1 once daily by oral gavage for 28 days, or administered the corresponding dose of cisplatin once a week on days 0, 7, 14 and 21 by intravenous injection. The usual dose of cisplatin is 4 to 6 mg / kg once a week, and the single dose MTD reported in Balb / c nude mice is 6 mg / kg (Aston W., et al., BMC Cancer, 17: 684 (2017)).

[0212] Body weight was measured every day. Tolerance was assessed by monitoring body weight and calculating the percentage change in body weight relative to the body weight on the day the treatment started (day 0), as shown in Figures 1-3. If 20% of the mice in the group died spontaneously or lost ≥20% of their weight, the treatment was considered intolerant. Based on these criteria, the MTD combination was determined to be compound 1 (100 mg / kg) and cisplatin (6 mg / kg). The ability to treat mice with a 4-week dose of 6 mg / kg cisplatin and a daily dose of 100 mg / kg compound 1 showed that the combination was well tolerated because the dosing frequency of cisplatin was typically less than once a week or less than 6 mg / kg in combined therapeutic efficacy studies with other compounds. Example 2: In vitro assay Clonogenic assay

[0213] In vitro experiments were performed on various cell lines using the colony forming unit (CFU) assay. The CFU assay first involves determining what cell seeding density can form clearly dispersed colonies on a six-well plate when allowed to grow for about 14 days. Once this density is determined, cells are seeded into culture dishes on day 1, and on day 0, the USP1 inhibitor of compound 1 is treated with DMSO or 300nM, as well as increasing concentrations of temozolomide (316nM, 1μM, 3.16μM, 10μM, or 31.6μM), cisplatin (3.16nM, 10nM, 31.6nM, 100nM, 316nM, 1μM, or 3.16μM), mitomycin C (1nM, 3.16nM, 10nM, 31.6nM, 100nM, 316nM, 1μM), gemcitabine (31.6pM, 100 pM, 316pM, 1nM, 3.16nM), pemetrexed (31.6nM, 100nM, 316nM, 1μM, 3.16μM), camptothecin (316pM, 1nM, 3.16nM, 10nM, 31.6nM, 100nM, 316nM), doxorubicin (10nM, 31.6nM, 100nM, 316nM, 1μM), etoposide (31.6nM, 100nM, 316nM, 1μM, 3.16μM), or paclitaxel (3.16nM, 10nM, 31.6nM, 100nM, 316nM). On day 8, the medium was changed to contain the appropriate concentration of DMSO, USP1 inhibitor, temozolomide, cisplatin, mitomycin C, gemcitabine, pemetrexed, camptothecin, doxorubicin, etoposide, or paclitaxel. Around day 14, when clearly scattered colonies were visible in the DMSO-treated wells, the cells were fixed and stained with 0.1% crystal violet in 10% ethanol for 20 minutes at room temperature. The plates were imaged, and the amount of crystal violet staining in each well was quantified by extracting the crystal violet into 10% acetic acid and measuring the absorbance at 565 nm. The CFU results are shown in Table 1. Table 1. Chemotherapy nM IC 50 (Collaborative Scoring) Temozolomide ("temozol"), cisplatin ("Cis"), mitomycin C ("Mito.C."), gemcitabine ("gem"), pemetrexed ("pemetrex"), camptothecin ("campto"), doxorubicin ("dox."), etoposide ("Etop"), or paclitaxel ("Pacli").

[0214] For some cell lines, multiple IC50 The values ​​are separated by commas. The synergy scores are in parentheses. For example, for the combination test of compound 1 with camptothecin in the pancreatic cell line ASPC1, three individual IC 50 value of 3, and the synergy score was calculated to be (-5).

[0215] The results in Table 1 show that synergy was detected in cell lines treated with a combination of a USP1 inhibitor and camptothecin, cisplatin or mitomycin C. In certain cell lines, the combinations of the present disclosure were synergistic. In some aspects, the combinations were determined to have a Bliss score of about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, or about 25. Example 3: Antitumor activity of Compound 1 co-crystal in combination with cisplatin in a breast xenograft model derived from the MDA-MB-436 cell line in NOD SCID mice

[0216] The antitumor activity of USP1 inhibitor of Compound 1 cocrystal in combination with cisplatin was evaluated in mice in a mammary gland xenograft model derived from the MDA-MB-436 cell line using non-obese diabetic / severe combined immunodeficient (NOD SCID) mice, as FIG. 6A to FIG. 6B 1×10 7 MDA-MB-436 cells. When the tumor volume reaches about 240 mm 3 At 1 pm, mice were randomly divided into 5 groups and assigned to the following groups: control group, cisplatin (2 mg / kg), compound 1 (100 mg / kg), or a combination of compound 1 (100 mg / kg) and cisplatin (2 mg / kg). Cisplatin was injected intravenously via the tail vein once a week for a total of 4 doses. Compound 1 was administered once a day by oral gavage for 28 days. Body weight and tumor volume were measured twice a week. The mean tumor volume and standard error of the mean were calculated for each treatment group.

[0217] Fig. 6A The data in showed that the combination treatment group exhibited more durable antitumor activity in a subcutaneous mouse model derived from the MDA-MB-436 cell line compared with equivalent doses of compound 1 or cisplatin single agents.

[0218] The tolerability of cisplatin (2 mg / kg) and compound 1 (100 mg / kg) in the combined efficacy study was assessed by monitoring body weight and calculating the body weight change (percentage relative to the body weight on the treatment start day (day 0)), as follows: Figure 6B shown. Example 4: Antitumor activity of Compound 1 co-crystal in combination with cisplatin in the HBCx-8 patient-derived breast xenograft model in nude mice

[0219] The antitumor activity of USP1 inhibitors of Compound 1 co-crystals in combination with cisplatin was evaluated in mice (in the HBCx-8 patient-derived breast xenograft model in nude mice), as FIG. 7A to FIG. 7B Six to nine-week-old female athymic nude mice from Envigo were anesthetized and a 20 mm 3 Tumor fragments were placed subcutaneously. When the tumor volume reached approximately 100 mm 3 At 1 pm, mice were randomly divided into 3 groups and assigned to the following groups: control group, compound 1 (100 mg / kg), cisplatin (5 mg / kg), or a combination of compound 1 (100 mg / kg) and cisplatin (5 mg / kg). Cisplatin was administered intravenously via the tail vein once a week for a total of 3 doses. Compound 1 was administered orally by gavage once a day for 42 days. Body weight and tumor volume were measured twice a week. The mean tumor volume and standard error of the mean were calculated for each treatment group.

[0220] Fig. 7A The data in the study showed that the combination treatment group exhibited more durable antitumor activity in the HBCx-8 patient-derived subcutaneous mouse model compared with equivalent doses of compound 1 or cisplatin single agents.

[0221] The tolerability of cisplatin (5 mg / kg) and compound 1 (100 mg / kg) in the combined efficacy study was assessed by monitoring body weight and calculating the body weight change (percentage relative to the body weight on the day of treatment initiation (day 0)). Figure 7B shown. Example 5: Antitumor activity of Compound 1 co-crystal in combination with cisplatin in the HBCx-11 patient-derived breast xenograft model in nude mice

[0222] The antitumor activity of USP1 inhibitors of Compound 1 co-crystals in combination with cisplatin was evaluated in mice (in the HBCx-11 patient-derived breast xenograft model in nude mice), as FIG. 8A to FIG. 8B Six to nine-week-old female athymic nude mice from Envigo were anesthetized and a 20 mm 3 Tumor fragments were placed subcutaneously. When the tumor volume reached 75 to 196 mm 3At 1 pm, mice were randomly divided into 3 groups and assigned to the following groups: control group, compound 1 (100 mg / kg), cisplatin (3 mg / kg), or a combination of compound 1 (100 mg / kg) and cisplatin (3 mg / kg). Cisplatin was administered intravenously via the tail vein once a week for a total of 4 doses. Compound 1 was administered orally by gavage once a day for 28 days. Body weight and tumor volume were measured twice a week. The mean tumor volume and standard error of the mean were calculated for each treatment group.

[0223] Fig. 8A The data in the study showed that the combination therapy group exhibited superior and more durable antitumor activity in the HBCx-11 patient-derived subcutaneous mouse model compared with equivalent doses of compound 1 or cisplatin single agents.

[0224] The tolerability of cisplatin (3 mg / kg) and compound 1 (100 mg / kg) in the combined efficacy study was assessed by monitoring body weight and calculating the body weight change (percentage relative to the body weight on the treatment start day (day 0)), as follows: Figure 8B shown. ***

[0225] All patents and publications cited herein are incorporated by reference in their entirety.

Claims

1. A method of treating cancer in a subject comprising administering to the subject (i) a chemotherapeutic agent and (ii) an ubiquitin-specific processing protease 1 (USP1) inhibitor having Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein: X 1 and X 2 Each independently selected from N and CR 2 ; R 1 and R 2 are each independently selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; R 3 is optionally substituted phenyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyrazinyl, optionally substituted pyridazinyl or optionally substituted pyrazolyl; X 11 and X 12 are each independently selected from N and CH; R 5′ is selected from hydrogen, optionally substituted (C1-C6) alkyl, optionally substituted (C2-C6) alkenyl, optionally substituted (C2-C6) alkynyl, optionally substituted (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, cyano, halogen, sulfonamido, -C(=O)R 23 、-C(=O)OR 24 、-NR 32a R 32b 、-NR 31a C(=O)R 25 、-NR 31a C(=O)NR 31a R 31b 、-C(=O)NR 31a R 31b 、-S(O)2R 27 、-NR 31a S02R 27 , optionally substituted (C6-C 14 ) aryl, optionally substituted (C6-C 14 )ar-(C1-C2)alkyl, optionally substituted heteroaryl, optionally substituted heteroar-(C1-C2)alkyl, optionally substituted (C3-C8)cycloalkyl, optionally substituted ((C3-C8)cycloalkyl)-(C1-C2)alkyl, optionally substituted heterocycle, optionally substituted heterocycle-(C1-C2)alkyl, optionally substituted -O-(C6-C 14 )aryl, optionally substituted -O-(C6-C 14 )ar-(C1-C2)alkyl, optionally substituted-O-heteroaryl, optionally substituted-O-heteroar-(C1-C2)alkyl, optionally substituted-O-(C3-C8)cycloalkyl, optionally substituted-O-((C3-C8)cycloalkyl)-(C1-C2)alkyl, optionally substituted-O-heterocycle, optionally substituted-O-heterocycle-(C1-C2)alkyl; R 5 is selected from optionally substituted (C1-C6) alkyl, optionally substituted (C2-C6) alkenyl, optionally substituted (C2-C6) alkynyl, optionally substituted (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, cyano, halogen, sulfonamido, -C(=O)R 23 、-C(=O)OR 24 、-NR 32a R 32b 、-NR 31a C(=O)R 25 、-NR 31a C(=O)NR 31a R 31b 、-C(=O)NR 31a R 31b 、-S(O)2R 27 、-NR 31a S02R 27 , optionally substituted (C6-C 14 ) aryl, optionally substituted (C6-C 14 )ar-(C1-C2)alkyl, optionally substituted heteroaryl, optionally substituted heteroar-(C1-C2)alkyl, optionally substituted (C3-C8)cycloalkyl, optionally substituted ((C3-C8)cycloalkyl)-(C1-C2)alkyl, optionally substituted heterocycle, optionally substituted heterocycle-(C1-C2)alkyl, optionally substituted -O-(C6-C 14 )aryl, optionally substituted -O-(C6-C 14 )ar-(C1-C2)alkyl, optionally substituted-O-heteroaryl, optionally substituted-O-heteroar-(C1-C2)alkyl, optionally substituted-O-(C3-C8)cycloalkyl, optionally substituted-O-((C3-C8)cycloalkyl)-(C1-C2)alkyl, optionally substituted-O-heterocycle, optionally substituted-O-heterocycle-(C1-C2)alkyl; or R on adjacent atoms 5 One of them and R 5′ One of them and the atoms to which they are attached together form an optionally substituted (C6-C 14 ) aromatic ring; or one of R5 on adjacent atoms and R 5′ One of them and the atoms to which they are attached together form an optionally substituted heteroaryl ring; or R on adjacent atoms 5 One of them and R 5′ One of them and the atoms to which they are attached together form an optionally substituted (C3-C8) cycloalkyl ring; or R on the adjacent atom 5 One of them and R 5′ One of them and the atoms to which they are attached together form an optionally substituted heterocycloalkyl ring; or R on adjacent atoms 5 One of them and R 5′ or R on adjacent atoms together form an optionally substituted spirocycloalkyl ring on the same atom to which they are attached; 5′ One of them and R 5 One of the forms taken together at the same atom to which they are attached forms an optionally substituted spiroheterocycloalkyl ring; R 6 and R 7 are each independently selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; R 23 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, amino, alkylamino, dialkylamino, cycloalkylamino, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkylamino)alkyl, (cycloalkyl)alkyl, aralkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, (amino)(hydroxy)alkyl, (aralkylamino)alkyl, optionally substituted heterocyclo, optionally substituted heteroaryl, optionally substituted aryl, and optionally substituted cycloalkyl; R 31a and R 31b are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, alkoxyalkyl, cycloalkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, aralkyl, and (heteroaryl)alkyl; and R 24 , R 25 , R 27 , R 32a and R 32b each is independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, amino, alkylamino, dialkylamino, cycloalkylamino, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkylamino)alkyl, (cycloalkyl)alkyl, aralkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, (amino)(hydroxy)alkyl, (aralkylamino)alkyl, alkoxyalkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted aryl, and optionally substituted cycloalkyl.

2. A method for delaying, reducing and / or preventing tumor rebound in a subject, comprising administering to the subject (i) a chemotherapeutic agent and (ii) an inhibitor of ubiquitin-specific processing protease 1 (USP1) having Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein: X 1 and X 2 Each independently selected from N and CR 2 ; R 1 and R 2 are each independently selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; R 3 is optionally substituted phenyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyrazinyl, optionally substituted pyridazinyl or optionally substituted pyrazolyl; X 11 and X 12 are each independently selected from N and CH; R 5′ is selected from hydrogen, optionally substituted (C1-C6) alkyl, optionally substituted (C2-C6) alkenyl, optionally substituted (C2-C6) alkynyl, optionally substituted (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, cyano, halogen, sulfonamide, -C(=O)R 23 、-C(=O)OR 24 、-NR 32a R 32b 、-NR 31a C(=O)R 25 、-NR 31a C(=O)NR 31a R 31b 、-C(=O)NR 31a R 31b 、-S(O)2R 27 、-NR 31a S02R 27 , optionally substituted (C6-C 14 ) aryl, optionally substituted (C6-C 14 )ar-(C1-C2)alkyl, optionally substituted heteroaryl, optionally substituted heteroar-(C1-C2)alkyl, optionally substituted (C3-C8)cycloalkyl, optionally substituted ((C3-C8)cycloalkyl)-(C1-C2)alkyl, optionally substituted heterocycle, optionally substituted heterocycle-(C1-C2)alkyl, optionally substituted -O-(C6-C 14 )aryl, optionally substituted -O-(C6-C 14 )ar-(C1-C2)alkyl, optionally substituted-O-heteroaryl, optionally substituted-O-heteroar-(C1-C2)alkyl, optionally substituted-O-(C3-C8)cycloalkyl, optionally substituted-O-((C3-C8)cycloalkyl)-(C1-C2)alkyl, optionally substituted-O-heterocycle, optionally substituted-O-heterocycle-(C1-C2)alkyl; R 5 is selected from optionally substituted (C1-C6) alkyl, optionally substituted (C2-C6) alkenyl, optionally substituted (C2-C6) alkynyl, optionally substituted (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, cyano, halogen, sulfonamido, -C(=O)R 23 、-C(=O)OR 24 、-NR 32a R 32b 、-NR 31a C(=O)R 25 、-NR 31a C(=O)NR 31a R 31b 、-C(=O)NR 31a R 31b 、-S(O)2R 27 、-NR 31a S02R 27 , optionally substituted (C6-C 14 ) aryl, optionally substituted (C6-C 14 )ar-(C1-C2)alkyl, optionally substituted heteroaryl, optionally substituted heteroar-(C1-C2)alkyl, optionally substituted (C3-C8)cycloalkyl, optionally substituted ((C3-C8)cycloalkyl)-(C1-C2)alkyl, optionally substituted heterocycle, optionally substituted heterocycle-(C1-C2)alkyl, optionally substituted -O-(C6-C 14 )aryl, optionally substituted -O-(C6-C 14 )ar-(C1-C2)alkyl, optionally substituted-O-heteroaryl, optionally substituted-O-heteroar-(C1-C2)alkyl, optionally substituted-O-(C3-C8)cycloalkyl, optionally substituted-O-((C3-C8)cycloalkyl)-(C1-C2)alkyl, optionally substituted-O-heterocycle, optionally substituted-O-heterocycle-(C1-C2)alkyl; or R on adjacent atoms 5 One of them and R 5′ One of them and the atoms to which they are attached together form an optionally substituted (C6-C 14 ) aromatic ring; or one of R5 on adjacent atoms and R 5′ One of them and the atoms to which they are attached together form an optionally substituted heteroaryl ring; or R on adjacent atoms 5 One of them and R 5′ One of them and the atoms to which they are attached together form an optionally substituted (C3-C8) cycloalkyl ring; or R on the adjacent atom 5 One of them and R 5′ One of them and the atoms to which they are attached together form an optionally substituted heterocycloalkyl ring; or R on adjacent atoms 5 One of them and R 5′ or R on adjacent atoms together form an optionally substituted spirocycloalkyl ring on the same atom to which they are attached; 5′ One of them and R 5 One of the forms taken together at the same atom to which they are attached forms an optionally substituted spiroheterocycloalkyl ring; R 6 and R 7 are each independently selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; R 23 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, amino, alkylamino, dialkylamino, cycloalkylamino, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkylamino)alkyl, (cycloalkyl)alkyl, aralkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, (amino)(hydroxy)alkyl, (aralkylamino)alkyl, optionally substituted heterocyclo, optionally substituted heteroaryl, optionally substituted aryl, and optionally substituted cycloalkyl; R 31a and R 31b are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, alkoxyalkyl, cycloalkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, aralkyl, and (heteroaryl)alkyl; and R 24 , R 25 , R 27 , R 32a and R 32b each is independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, amino, alkylamino, dialkylamino, cycloalkylamino, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkylamino)alkyl, (cycloalkyl)alkyl, aralkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, (amino)(hydroxy)alkyl, (aralkylamino)alkyl, alkoxyalkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted aryl, and optionally substituted cycloalkyl.

3. The method of claim 1 or 2, wherein the chemotherapeutic agent is a platinum, a monofunctional alkylating agent, a bifunctional alkylating agent, an antimetabolite, a topoisomerase inhibitor, or a combination thereof.

4. The method of claim 3, wherein the chemotherapeutic agent is a platinum selected from the group consisting of cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, nedaplatin and triplatin; optionally, wherein the platinum is cisplatin or carboplatin.

5. The method of claim 3, wherein the chemotherapeutic agent is a monofunctional alkylating agent selected from the group consisting of alkyl sulfonates, nitrosoureas, and temozolomide; or a bifunctional alkylating agent selected from the group consisting of nitrogen mustard and mitomycin C.

6. The method of claim 3, wherein the chemotherapeutic agent is an antimetabolite selected from the group consisting of gemcitabine, 5-fluorouracil, thiopurines, and folate analogs.

7. The method of claim 3, wherein the chemotherapeutic agent is a topoisomerase inhibitor selected from the group consisting of camptothecin, anthracycline and etoposide.

8. The method according to any one of claims 1 to 7, wherein the compound of formula I is provided as a co-crystal formed between a USP1 inhibitor of formula I and a pharmaceutically acceptable acid.

9. The method according to any one of claims 1 to 8, wherein the USP1 inhibitor has one of the following structures: or a pharmaceutically acceptable salt or solvate thereof, wherein X 1 and X 2 Each independently selected from N and CR 2 ; R 1 is selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; R 5 for: X 6 Selected from NR 13 and CR 18 ; X 7 Selected from NR 14 and CR 19 ; X 8 Selected from NR 15 and CR 20 ; X 9 Selected from NR 16 and CR 21 ; X 10 Selected from NR 17 and CR 22 ; R 13 , R 14 , R 15 , R 16 and R 17 each is absent or is independently selected from hydrogen, halogen, methyl, ethyl, isopropyl, cyclopropyl, methoxy, triazolyl, cyano, optionally substituted alkyl, amino, alkylamino, dialkylamino, difluoromethyl, trifluoromethyl, methylsulfonyl, and methylazetidinyl; and R 18 , R 19 , R 20 , R 21 and R 22 each independently selected from hydrogen, halogen, methyl, ethyl, isopropyl, cyclopropyl, methoxy, triazolyl, cyano, optionally substituted alkyl, amino, alkylamino, dialkylamino, difluoromethyl, trifluoromethyl, methylsulfonyl and methylazetidinyl; R 6 and R 7 are each independently selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; and R 8 , R 9 and R 11 each independently selected from hydrogen, halogen, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, heteroaryloxy, aralkylaralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, carboxyl, carboxylalkyl, alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, alkoxyalkyl, (amino)alkyl, hydroxyalkylamino, (alkylamino)alkyl, (dialkylamino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclyl)alkyl, (cycloalkylamino)alkyl, (C 1-4 haloalkoxy)alkyl or (heteroaryl)alkyl.

10. The method according to any one of claims 1-9, wherein the USP1 inhibitor is a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid, polymorph or co-crystal thereof.

11. The method according to any one of claims 1 to 9, wherein the USP1 inhibitor is a compound selected from the group consisting of: (a) Compound 1: (b) Compound 2: (c) Compound 3: and pharmaceutically acceptable salts, hydrates, solvates, amorphous solids or polymorphs thereof; or a pharmaceutically acceptable salt thereof; or its hydrates; or a solvate thereof; or its amorphous solid; or its polymorphs; or Its eutectic.

12. The method according to claim 11, wherein the USP1 inhibitor is Compound 1, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid or polymorph thereof; or wherein the USP1 inhibitor is Compound 1, or a co-crystal thereof; or wherein the USP1 inhibitor is Compound 2, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid or polymorph thereof; or wherein the USP1 inhibitor is Compound 2, or a co-crystal thereof; or wherein the USP1 inhibitor is compound 3, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid or polymorph thereof; or The USP1 inhibitor is compound 3, or a co-crystal thereof.

13. The method of any one of claims 1-12, wherein the USP1 inhibitor is provided in the form of a co-crystal formed between 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and a pharmaceutically acceptable acid.

14. The method according to claim 13, wherein the pharmaceutically acceptable acid is selected from the group consisting of gentisic acid, benzoic acid, salicylic acid and gallic acid; optionally, wherein the pharmaceutically acceptable acid is gentisic acid.

15. The method of any one of claims 1-14, wherein the subject is a mammal, optionally wherein the mammal is a human.

16. The method of any one of claims 1-15, wherein the subject's cancer cells are HRR positive.

17. The method of any one of claims 1-16, wherein the cancer or tumor is an advanced solid tumor.

18. The method of any one of claims 1-17, wherein the cancer or tumor is selected from the group consisting of lung cancer, non-small cell lung cancer (NSCLC), colon cancer, bladder cancer, osteosarcoma, ovarian cancer, skin cancer, uterine cancer, peritoneal cancer, endometrial cancer, pancreatic cancer, gastric cancer, bile duct cancer, and breast cancer.

19. The method of any one of claims 1-18, wherein the chemotherapeutic agent and the USP1 inhibitor are administered sequentially.

20. The method of any one of claims 1-18, wherein the chemotherapeutic agent and the USP1 inhibitor are administered simultaneously.

21. The method of any one of claims 1-20, wherein the chemotherapeutic agent and the USP1 inhibitor are administered in therapeutically effective amounts sufficient to produce one or more therapeutic effects selected from the group consisting of (i) reduction in tumor size, (ii) increase in tumor regression rate, and (iii) reduction or inhibition of tumor growth; or The chemotherapeutic agent and the USP1 inhibitor are administered in effective amounts to reduce unacceptable toxicity and / or unacceptable adverse effects of the chemotherapeutic agent administered as a monotherapy.

22. The method according to claim 1, wherein said chemotherapeutic agent and said USP1 inhibitor delay, reduce and / or prevent tumor rebound.

23. The method of any one of claims 1, 2, and 8-22, wherein the USP1 inhibitor, gemcitabine, and carboplatin are administered; optionally, wherein the subject has ovarian cancer, triple-negative breast cancer, or non-small cell lung cancer.

24. The method of any one of claims 1, 2, and 8-22, wherein the USP1 inhibitor, folinate, 5-fluorouracil, and oxaliplatin are administered; optionally, wherein the subject has colorectal cancer, pancreatic cancer, esophageal cancer, or gastric cancer.

25. The method of any one of claims 1-24, wherein the cancer or tumor has been previously treated with a platinum therapy, optionally wherein the cancer or tumor is platinum-resistant or platinum-refractory; optionally wherein the platinum therapy is selected from the group consisting of cisplatin, carboplatin, oxaliplatin, and combinations thereof.

26. A composition comprising (i) a chemotherapeutic agent and (ii) an ubiquitin-specific processing protease 1 (USP1) inhibitor, wherein the USP1 inhibitor is a compound having Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein: X 1 and X 2 Each independently selected from N and CR 2 ; R 1 and R 2 are each independently selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; R 3 is optionally substituted phenyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyrazinyl, optionally substituted pyridazinyl or optionally substituted pyrazolyl; X 11 and X 12 are each independently selected from N and CH; R 5′ is selected from hydrogen, optionally substituted (C1-C6) alkyl, optionally substituted (C2-C6) alkenyl, optionally substituted (C2-C6) alkynyl, optionally substituted (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, cyano, halogen, sulfonamido, -C(=O)R 23 、-C(=O)OR 24 、-NR 32a R 32b 、-NR 31a C(=O)R 25 、-NR 31a C(=O)NR 31a R 31b 、-C(=O)NR 31a R 31b 、-S(O)2R 27 、-NR 31a S02R 27 , optionally substituted (C6-C 14 ) aryl, optionally substituted (C6-C 14 )ar-(C1-C2)alkyl, optionally substituted heteroaryl, optionally substituted heteroar-(C1-C2)alkyl, optionally substituted (C3-C8)cycloalkyl, optionally substituted ((C3-C8)cycloalkyl)-(C1-C2)alkyl, optionally substituted heterocycle, optionally substituted heterocycle-(C1-C2)alkyl, optionally substituted -O-(C6-C 14 )aryl, optionally substituted -O-(C6-C 14 )ar-(C1-C2)alkyl, optionally substituted-O-heteroaryl, optionally substituted-O-heteroar-(C1-C2)alkyl, optionally substituted-O-(C3-C8)cycloalkyl, optionally substituted-O-((C3-C8)cycloalkyl)-(C1-C2)alkyl, optionally substituted-O-heterocycle, optionally substituted-O-heterocycle-(C1-C2)alkyl; R 5 is selected from optionally substituted (C1-C6) alkyl, optionally substituted (C2-C6) alkenyl, optionally substituted (C2-C6) alkynyl, optionally substituted (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, cyano, halogen, sulfonamido, -C(=O)R 23 、-C(=O)OR 24 、-NR 32a R 32b 、-NR 31a C(=O)R 25 、-NR 31a C(=O)NR 31a R 31b 、-C(=O)NR 31a R 31b 、-S(O)2R 27 、-NR 31a S02R 27 , optionally substituted (C6-C 14 ) aryl, optionally substituted (C6-C 14 )ar-(C1-C2)alkyl, optionally substituted heteroaryl, optionally substituted heteroar-(C1-C2)alkyl, optionally substituted (C3-C8)cycloalkyl, optionally substituted ((C3-C8)cycloalkyl)-(C1-C2)alkyl, optionally substituted heterocycle, optionally substituted heterocycle-(C1-C2)alkyl, optionally substituted -O-(C6-C 14 )aryl, optionally substituted -O-(C6-C 14 )ar-(C1-C2)alkyl, optionally substituted-O-heteroaryl, optionally substituted-O-heteroar-(C1-C2)alkyl, optionally substituted-O-(C3-C8)cycloalkyl, optionally substituted-O-((C3-C8)cycloalkyl)-(C1-C2)alkyl, optionally substituted-O-heterocycle, optionally substituted-O-heterocycle-(C1-C2)alkyl; or R on adjacent atoms 5 One of them and R 5′ One of them and the atoms to which they are attached together form an optionally substituted (C6-C 14 ) aromatic ring; or one of R5 on adjacent atoms and R 5′ One of them and the atoms to which they are attached together form an optionally substituted heteroaryl ring; or R on adjacent atoms 5 One of them and R 5′ One of them and the atoms to which they are attached together form an optionally substituted (C3-C8) cycloalkyl ring; or R on the adjacent atom 5 One of them and R 5′ One of them and the atoms to which they are attached together form an optionally substituted heterocycloalkyl ring; or R on adjacent atoms 5 One of them and R 5′ or R on adjacent atoms together form an optionally substituted spirocycloalkyl ring on the same atom to which they are attached; 5′ One of them and R 5 One of the forms taken together at the same atom to which they are attached forms an optionally substituted spiroheterocycloalkyl ring; R 6 and R 7 are each independently selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; R 23 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, amino, alkylamino, dialkylamino, cycloalkylamino, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkylamino)alkyl, (cycloalkyl)alkyl, aralkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, (amino)(hydroxy)alkyl, (aralkylamino)alkyl, optionally substituted heterocyclo, optionally substituted heteroaryl, optionally substituted aryl, and optionally substituted cycloalkyl; R 31a and R 31b are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, alkoxyalkyl, cycloalkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, aralkyl, and (heteroaryl)alkyl; and R 24 , R 25 , R 27 , R 32a and R 32b each is independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, amino, alkylamino, dialkylamino, cycloalkylamino, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkylamino)alkyl, (cycloalkyl)alkyl, aralkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, (amino)(hydroxy)alkyl, (aralkylamino)alkyl, alkoxyalkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted aryl, and optionally substituted cycloalkyl.

27. The composition of claim 26, wherein the chemotherapeutic agent is a platinum, a monofunctional alkylating agent, a difunctional alkylating agent, an antimetabolite, a topoisomerase inhibitor, or a combination thereof.

28. The composition of claim 27, wherein the chemotherapeutic agent is a platinum selected from the group consisting of cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, nedaplatin and triplatin; optionally, wherein the chemotherapeutic agent is cisplatin or carboplatin; or wherein the chemotherapeutic agent is a monofunctional alkylating agent selected from the group consisting of alkyl sulfonates, nitrosoureas and temozolomide; or a bifunctional alkylating agent selected from the group consisting of nitrogen mustard and mitomycin C; or wherein the chemotherapeutic agent is an antimetabolite selected from the group consisting of gemcitabine, 5-fluorouracil, thiopurines and folic acid analogs; or wherein the chemotherapeutic agent is a topoisomerase inhibitor selected from the group consisting of camptothecins, anthracyclines and etoposide.

29. The composition of claim 27, wherein the chemotherapeutic agent comprises folinate, 5-fluorouracil and oxaliplatin.

30. The composition of any one of claims 26-29, wherein the USP1 inhibitor of Formula I has one of the following structures: or a pharmaceutically acceptable salt or solvate thereof, wherein X 1 and X 2 Each independently selected from N and CR 2 ; R 1 is selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; R 5 for: X 6 Selected from NR 13 and CR 18 ; X 7 Selected from NR 14 and CR 19 ; X 8 Selected from NR 15 and CR 20 ; X 9 Selected from NR 16 and CR 21 ; X 10 Selected from NR 17 and CR 22 ; R 13 , R 14 , R 15 , R 16 and R 17 each is absent or is independently selected from hydrogen, halogen, methyl, ethyl, isopropyl, cyclopropyl, methoxy, triazolyl, cyano, optionally substituted alkyl, amino, alkylamino, dialkylamino, difluoromethyl, trifluoromethyl, methylsulfonyl, and methylazetidinyl; and R 18 , R 19 , R 20 , R 21 and R 22 each independently selected from hydrogen, halogen, methyl, ethyl, isopropyl, cyclopropyl, methoxy, triazolyl, cyano, optionally substituted alkyl, amino, alkylamino, dialkylamino, difluoromethyl, trifluoromethyl, methylsulfonyl and methylazetidinyl; R 6 and R 7 are each independently selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; and R 8 , R 9 and R 11 each independently selected from hydrogen, halogen, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, heteroaryloxy, aralkylaralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, carboxyl, carboxylalkyl, alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, alkoxyalkyl, (amino)alkyl, hydroxyalkylamino, (alkylamino)alkyl, (dialkylamino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclyl)alkyl, (cycloalkylamino)alkyl, (C 1-4 haloalkoxy)alkyl or (heteroaryl)alkyl.

31. The composition according to any one of claims 26 to 30, wherein the compound of formula I is provided in the form of a co-crystal formed between the USP1 inhibitor of formula I and a pharmaceutically acceptable acid.

32. The composition according to any one of claims 26-30, wherein the USP1 inhibitor is selected from the group consisting of: (a) Compound 1: (b) Compound 2: (c) Compound 3: and pharmaceutically acceptable salts, hydrates, solvates, amorphous solids or polymorphs thereof; or a pharmaceutically acceptable salt thereof; or its hydrates; or a solvate thereof; or its amorphous solid; or its polymorphs; or Its eutectic.

33. The composition of claim 32, wherein the USP1 inhibitor is Compound 1, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid or polymorph thereof; or wherein the USP1 inhibitor is Compound 1, or a co-crystal thereof; or wherein the USP1 inhibitor is Compound 2, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid or polymorph thereof; or wherein the USP1 inhibitor is Compound 2, or a co-crystal thereof; or wherein the USP1 inhibitor is compound 3, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid or polymorph thereof; or The USP1 inhibitor is compound 3, or a co-crystal thereof.

34. The composition of any one of claims 26-33, wherein the USP1 inhibitor is a co-crystal formed between 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and a pharmaceutically acceptable acid.

35. The composition of claim 34, wherein the pharmaceutically acceptable acid is selected from the group consisting of gentisic acid, benzoic acid, salicylic acid and gallic acid; optionally, wherein the pharmaceutically acceptable acid is gentisic acid.

36. The composition of any one of claims 26-35, wherein the USP1 inhibitor and the chemotherapeutic agent are provided in separate dosage forms.

37. The composition of any one of claims 26-36, wherein the USP1 inhibitor is provided in an oral dosage form.

38. The composition of any one of claims 26-37, wherein the chemotherapeutic agent is provided in an injectable dosage form; or The chemotherapeutic agent is provided in an oral dosage form.

39. A composition according to any one of claims 26-38 for use in the treatment of cancer.

40. Use of the composition according to any one of claims 26-38 for the manufacture of a medicament for treating cancer.

41. A kit comprising a composition according to any one of claims 26-38, and instructions for administering the composition to a subject having cancer.

42. The composition of claim 39 or the use of claim 40 or the kit of claim 41, wherein the cancer is an advanced solid tumor; or wherein the cancer is selected from the group consisting of lung cancer, non-small cell lung cancer (NSCLC), colon cancer, bladder cancer, osteosarcoma, ovarian cancer, skin cancer, uterine cancer, peritoneal cancer, endometrial cancer, pancreatic cancer, gastric cancer, bile duct cancer and breast cancer; or wherein the cancer has been previously treated with platinum therapy, optionally wherein the cancer or tumor is platinum-resistant or platinum-refractory, optionally wherein the platinum therapy is selected from the group consisting of cisplatin, carboplatin, oxaliplatin and combinations thereof.